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A b stract
Prostate cancer is the second leading cause of death from cancer in North American
men, with a reported 32,050 deaths in the U.S. alone for 2010; lung cancer is reported
as the number one leading cause of death from cancer in both men and women in
North America, its estimated death toll in the U.S. alone in 2010 is over 157,000.
One method of treating prostate cancer patients nowadays is by Low Dose Rate
Brachytherapy, a process where radioactive seeds are placed in or near the tumor site
to kill cancerous cells. For lung cancer, brachytherapy has begun to attract attention
due to the advent of robotics assistance and there is increasing research currently in
the area. While brachytherapy is gaining popularity as a commonly practiced method
for treating cancer patients, the procedure itself has several drawbacks that require
further research. One such drawback is that the dosimetry plan created based on the
pre-operative imaging may not be accurate due to (a) the change in the tumor’s size as
a result of the time elapsed between pre-operative imaging and seed implantation; and
(b) movement of the organ under treatment from the position and orientation in pre
operative imaging; this is particularly important in the case of lung brachytherapy
as it would have to take into account lung deflation and respiratory and cardiac
motions as well. In addition, seeds may be misplaced during implantation as a result
of limitation of the manual or robotic procedures. When this happens, the final dose
coverage of the tumor is no longer the same as the intended coverage in the dosimetry
plan.
In this thesis, the development, implementation and evaluation of two algorithms
are presented. The first algorithm is the pre-planning algorithm, which aims to reduce
m

the errors in the dosimetry plan caused by the change in the tumor’s size by providing
a mechanism to perform dosimetry planning on-line. By doing this, the first algorithm
can also eliminate the need for the patient to be imaged twice, so that the same set
of images can be used for dosimetry planning as well as seed implantation. The
second algorithm deals with intra-operative dynamic dose optimization, where real
time seed compensation is performed to compensate for any seed misplacements so
that an optimal final coverage can be achieved. The results of the experimental
evaluation performed in this project indicate that these algorithms are feasible and
have the potential to be applied in the operating room following appropriate animal
and clinical validation.
Keywords: LDR Brachytherapy, Lung Cancer, Prostate Cancer, Dosimetry, Pre
planning.
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1

C h apter 1
In trod u ction
Cancer commonly manifests itself as malignant tumors that are fast growing and in
vade surrounding tissue and cells, new tumor growth can also occur at other locations
through a process known as metastasis. Treating the malignant tumor at an early
stage is highly desirable to prevent métastasés, with surgical removal/resection (such
as prostatectomy for prostate cancer or lobectomy for lung cancer) and chemotherapy
being the traditional and commonly practiced methods. Other treatment methods are
also available, such as the use of Hormonal Therapy (HT) for prostate cancer, which
targets one specific type of cancer, is a procedure where testosterone production is
decreased.
Radiation therapy is another technique for treating cancer, it uses high energy
rays, usually in kilo-electronvolts (keV) or mega-electronvolts (MeV) to kill the tumor
[1]. A traditional form of radiation therapy is the External Beam Radiotherapy
(EBR). In EBR, keV x-rays, also known as superficial x-rays, are used for skin cancer
and superficial structures; whereas MeV x-rays, also known as deep x-rays, are used
for tumors that are deeply-seated, such as on the bladder, prostate, lung and brain
etc. The application of radiation therapy on internal organs must be done with care
since the high energy beam kills all cells that are within range, be it cancerous or
healthy. Therefore the most difficult task in radiation therapy is to target the tumor
cells only.
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1.1

P r o sta te and Lung B rachyth erap y

Brachytherapy, which translates to short-range-therapy, is a more recent development
in radiation therapy compared to EBR. The biggest advantage of brachytherapy over
other treatment methods from radiation therapy is that it is both safer and less timeconsuming. In brachytherapy, it is possible to achieve a high ratio of cancer dose to
normal tissue dose by placing radiation sources inside or next to cancerous tissue,
thus avoiding harming normal and healthy tissue during the treatment process, and
is an improvement over EBR. Nevertheless, no method is proven to be 100% safe and
all may lead to undesirable side effects.
There are mainly three categories of brachytherapy in use today, they are Low
Dose Rate (LDR), Medium Dose Rate (MDR) and High Dose Rate (HDR). The
biggest difference between all these categories is the dose administered to the patient
during treatment. For example, LDR is generally between 0.4G?/*1 to 2Gy per hour,
MDR is from 2Gy to 12Gy per hour, while HDR is usually more than 12Gy per hour.
The focus of this thesis is on LDR brachytherapy in the prostate and the lung.
The LDR brachytherapy treatment procedure involves permanently placing the
radioactive seeds inside the patient, which is why it can also be referred to as per
manent brachytherapy, is usually composed of four steps with the support of several
medical imaging modalities, such as transrectal ultrasound (TRUS), computed tomog
raphy (CT) and radiography. The first step, which is known as pre-implant volume
study, uses either TRUS or CT to determine the volume of the target [2, 3, 4]; the
second step is called pre-planning, where a dosimetry plan is created by the radiation
oncologist in an off-line environment; thus no imaging is required for this step. TRUS
1. Gray (symbol: Gy) is the SI unit of absorbed radiation dose of ionizing radiation.
1Gy = ljL = 1m2-s~2
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and radiography are usually used in step three, which is commonly known as seed
implantation [2, 3]. CT is required some time after the implant to assess the quality
of the procedure in step four, known as post-implantation [2, 3].

1.1.1

Brachytherapy Seeds

According to [5], there are three types of seeds commonly selected for interstitial
brachytherapy, they are Iodine 125 (125I), Palladium 103 (103Pd) and Iridium 192
(192Ir), while the less frequently used seeds are, Cesium 137 (137Cs) and Cobalt 60
(60Co). All the elements listed above are the unstable radioisotopes of their stable
atoms. For instance, the stable atom of Iodine has 53 protons and 74 neutrons,
the sum of which gives an atomic mass of 127 for the stable form of Iodine. The
radioisotope 125I on the other hand, has only 72 neutrons. Similarly, 103Pd has 57
neutrons while the stable 106Pd has 60 neutrons. A more detailed description on the
properties and radioactivity of 1251 are given in Appendix D. Section 1.1.1.1 discusses
125I in more detail; here 103Pd and 192Ir are briefly examined.
The short half-life (7 \/2) of 103Pd of 17.0 days means that it is only good for per
manent implants [5], and is a common replacement for 125I in permanent brachyther
apy. Even the geometries of 1(l3Pd sources are very comparable to that of 125I sources.
The high initial dose rate of 103Pd is appropriate when applied in interstitial implan
tation of rapidly proliferating tumors. The Half Value Layer (HVL) for 103Pd at
0.008mm is lower than the HVL for 125I, which is given by [6] as 0.025mm. HVL is
discussed in more detail in Appendix D.
192Ir, has a longer half-life at 73.83 days [5]. They appear as small cylindrical
sources for interstitial use in the United States, which are approximately 3mm long
and 0.5mm in diameter. In Europe however, 192Ir is most commonly used in the
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Figure 1.1: Size of brachytherapy seeds
form of a wire. As reported in [7], 192Ir has now established itself as the preferred
radionuclide for all temporary brachytherapy applications, which are not LDR.
1.1.1.1

Iodine 125

By comparison, 125I is by far the most commonly used seed for LDR brachytherapy
(details on the decay and radioactivity of 125I are given in Appendix D). Three
models of the 125I seeds are available, they are the 6702 and 6711 type manufactured
by Amersham and the 2300 type marketed by Best Industries. The 2300 type is said
to be more isotropic in dose pattern due to the presence of iodine on the ends of the
seed and on the surface of the tungsten wire that is inside the titanium encapsulation
[8]. Even though the design and appearance of one seed differs from those of another,
the size of all these seeds are generally no bigger than a grain of rice.
This thesis uses the 6711 model of 125I seed by Amersham; reference [5] provides
detailed information on this type of seed. The half-life,

of this seed is given by

[5] as 59.4 days, which translates to 1426 hours. This type of seed is approximately
4.5mm in length, and its diameter is about 0.8mm, enclosed in a 0.05mm thick
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titanium wall. This seed type offers air kerma strength of up to 6.3f/2, which is
equivalent to an apparent activity of 5mCz3. The interior design of the Amersham
seed consists of a hollow cylinder made of a double-walled titanium tube. Two of
the advantages offered by this designed are that, one there is a higher isotropy of
the irradiation field around the source, and two there is a reduced chance of seed
migration [7].

1.1.2

State-of-the-art Prostate Brachytherapy

Despite brachytherapy being more advantageous than other radiation therapy treat
ment methods as mentioned previously, it is not always recommended for all cancer
patients. Even when brachytherapy is selected as the primary treatment method,
additional therapy is sometimes required to complete the treatment process [6]. Re
gardless of the treatment strategy employed, the long-term cure rate is always favor
able for patients with early stage cancer. For example, patients with low-risk prostate
cancer are usually recommended for the four-step prostate brachytherapy. Low-risk
prostate cancer is defined for patients that have a Prostate-Specific Antigen (PSA)
level of 10ng/m L or less, a Gleason score of 6 or less, and clinical stage T2a or less
[6]. PSA, the Gleason score and prostate cancer staging are discussed in more detail
in Appendix A. The reason for choosing the four-step procedure for low-risk prostate
cancer is that the disease would be more likely to have been confined to the prostate
in these patients. In addition, there are other factors that could influence the decision
to offer brachytherapy, such as the size of the prostate must be less than 60cc [9].
Once a patient is found to have met these criteria, and thus be eligible for prostate
2. U, unit for air kerma strength, usually specified at lm. 1U = 1fiGy ■m2 ■h 1 [5]
3. Curie (symbol: Ci) is a unit of radioactivity. 1C* = 3.7 x 1010 decays per second
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Figure 1.2: A sample seed template used for prostate brachytherapy
brachytherapy, an ultrasound-guided prostate volume study must be performed as
the first step.
1.1.2.1

Step 1 - Pre-implant Volume Study

During the volume study, the size of the gland and the relation of the gland to the
pubic arch are assessed; this study also determines the target volume and tracks the
urethra through the prostate. This volume study is carried out with the patient
sedated in the lithotomy (treatment) position [9], usually with the aid of a TRUS
probe to visualize the prostate in the transverse and sagittal dimensions [10]. This
probe is mounted on a stabilization apparatus that’s affixed to the Operating Room
(OR) table with a template grid attached, the angle of the mount and the probe are
recorded. A sample template is shown in Fig. 1.2, the purpose of which is to assist
needle insertion. The probe is then lubricated with ultrasound (US) jelly before being
inserted into the rectum, this is to reduce air interference between the US probe and
the rectal wall to achieve the best visualization of the prostate. CT or Magnetic
Resonance Imaging (MRI) could also be used in place of US, though due to practical
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Figure 1.3: TRUS probe and 2D input US images
operating room constraints, these modalities are only available at a limited number
of institutions [10].
The set of images of the prostate are acquired at < 1° intervals by the TRUS
probe as the probe is rotated about its axis. The acquired images appear as a fan
and are in polar coordinates. A polar to rectangular transformation is required to
construct the 3D volume in cartesian coordinates before these images can be used for
contouring purposes. Figure 1.3 shows a graphical representation of the probe and
the images obtained which are then used as input images for the polar to rectangular
transformation.
Once the prostate and the surrounding organs are displayed, contours can be
defined to identify the target and normal tissues. The contours of the target, namely
the prostate, should then be compared with the length of the prostate that was
measured on the sagittal views, the volume of the gland should also be recorded for
comparison purposes. Hormonal treatment may be applied to abnormally large glands
to shrink the prostate, the volume of which may decrease by as much as one third
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Figure 1.4: Cross-sectional view of the prescription contour enclosing the prostate
within 4 months of the treatment. For a prostate volume that is within the defined
limits, these contours and images can be transferred to a treatment-planning system
for step two of the procedure known as dosimetry planning, which is explained in the
next paragraph. The current image acquisition software found in clinics superimposes
a series of dots on the US images, which correspond to the holes in the seed template.
1.1.2.2

Step 2 - Pre-planning

The second step is called dosimetry planning, or pre-planning, the aim of which
is to calculate the seed positions required to deliver the desired dose to the entire
tumor volume [2]. During dosimetry planning, the intention is to enclose every crosssectional image of the prostate within the prescription dose contour, as shown in
Fig. 1.4. This is to ensure that the entire gland can receive a proper dose, since the
size of the prostate gland is relatively small. Pre-planning for lung cancer is rather
different, where only the tumors (and a specified margin around them) are to receive
the prescribed dose and not the entire organ.
In any case, there are usually dosimetry constraints that govern the dosimetry
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planning process. For example, a constraint of dosimetry planning for the prostate
is the amount of dose that can be delivered to the urethra. Reference [2] suggests
that as much as 125% of the prescribed dose can be delivered to the urethra, even
though the dose to the urethra should be kept as low as possible. Other constraints
may include the dose to the rectum and to the boundary of the prostate itself. All in
all, dosimetry planning tries to limit the number of low-dose regions or “cold spots”,
which may lead to tumor relapse, while the number of high-dose regions or “hot
spots” in normal tissues must also be limited, which may result in late complications
[6] such as the killing or damaging of healthy tissue. Due to the presence of the seed
template, the brachytherapy seeds are generally spaced at 10mm in the cranio-caudal
direction, which would be the direction coming out of the page as in Fig. 1.4. In
Cartesian coordinates, if the cranio-caudal direction is intepreted as the z-axis, then
the seeds are spaced at 5mm or more in the x and y directions, which are co-planar
to the direction shown by view in Fig. 1.4.
1.1.2.3

Step 3 - Seed Implantation

Seed implantation is the next step after dosimetry planning, which usually takes place
a few weeks after the volume study has been done [2], Before loading the seeds into
the brachytherapy needles for implatation, the seeds are unpacked first and then their
activity is checked in a calibrator. The activity defines the number of disintegrations
within a given time for a particular radioactive source, which is a measure of how
radioactive the source is; activity is discussed in more detail in Appendix C. The
loading and checking of the seeds are done under sterile conditions. The seeds are
then loaded in to the needles according to the dosimetry plan, also called a pre-plan.
A sample pre-plan of prostate brachytherapy is shown in Fig. 1.5, which contains
information for the ‘hole location’ of the needles expressed in terms of an alphabet and
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Figure 1.5: A sample pre-plan for prostate brachytherapy
a number that corresponds to the horizontal and vertical indices on the seed template
to provide the exact location of where the needle should be inserted. Furthermore,
the plan contains information on the depth at which the seeds should be deposited,
indicated by the values under ‘retraction’. The preloaded needles with the seeds are
kept within a shielded vault, they are only taken out of the vault and handed to the
physician when he or she is ready to insert each individual needle.
A stylet is placed after the train of seeds in each needle in order to push the seeds
out once the needle has been deposited at its destination. To protect the patient and
staff while the patient is being anaesthetised and placed in the lithotomy position
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again, the loaded needles are stored in a shielded loading box. The TRUS probe
and the seed template are then positioned to match the volume study positions as
closely as possible. Under the guidance of US imaging, each needle is taken in turn
and inserted through its assigned hole in the template to its desired depth. One
limitation related specifically to the prostate brachytherapy procedure is that the
seeds can only be placed in terms of grid and needle units, due to the presence of the
seed template and the fact that the seeds are spaced at a minimum of 0.5cm inside
the needles.
Once the needle is at the correct retraction depth, it is pulled back over the stylet
to deposit the train of seeds at their destinations in the prostate. In the event that
the needle has not been inserted through the correct hole in the template, or if the
seed has been deposited at an incorrect depth, the surgeon may even take out the
misplaced seeds using a procedure similar to the one described in [11]. These seeds
need to be taken out because if any seed is left in an unintended location, the final
coverage of the tumor will no longer be accurate since the location of the seeds will be
different to the pre-plan. The used needle and stylet are discarded and the rest of the
needles are inserted in the way described above. At the end of this step, radiography
is used to check the positioning of the seeds. The post-implant dosimetry check-up,
which is step four of the procedure, must be performed some time after the seed
implantation has taken place.
1.1.2.4

Step 4 - Post-implant Check-up

The post-implant check-up is usually conducted using CT, the main goal of this step
is for quality control purposes, as well as evaluating the dosimetry to the surrounding
Organs At Risk (OAR). The time between seed implantation and post-implant check
up have been suggested as anywhere between 1 to 30 days after seed implantation [9].

12
According to [9], most post-implant check-up is done 4 weeks after implantation to
allow the edema to subside. Ultrasound is not used in this step because the artifacts
from the implanted seeds may cause image degradation. The CT images are imported
into a treatment-planning system to identify the seeds in the prostate and analyze
the dosimetry data based on the contours defined for the prostate. The data of
importance are discussed in more detail in section 4.3.
The four-step prostate brachytherapy procedure described above suffers from a
change in the size and volume of the prostate between volume study and seed im
plantation, as mentioned previously in section 1.1.3 and in [9]. As a result, intra
operative planning has been reported in [2], [6] and [9]. One advantage discussed
in these literature is the improved accuracy of seed implantation since both the vol
ume study and seed implantation are carried out at the same time, which effectively
avoids any changes to the prostate compared to the four-step procedure; whereas in
the four-step procedure the time spent waiting between the volume study and the ac
tual implantation might be long enough for the tumor to expand. Another advantage
is that the patient is required to be sedated only one time such that minimal dis
comfort exists whereas in the four-step procedure the patient must undergo sedation
for both volume study and seed implantation which means there is more discomfort.
The disadvantage, as mentioned in [2], is that more seeds tend to be wasted since the
precise number of seeds required is unknown in advance and they must be unpacked
and loaded in the OR.

1.1.3

Procedural Deficiencies

As mentioned above, the brachytherapy procedure at the moment is far from perfect.
In the prostate brachytherapy procedure, the dosimetry plan created in step two is
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based on the US images obtained from step one. The time between the creation of
the pre-plan to seed implantation in step three can be long enough for the tumor size
to change. Thus a pre-plan may no longer be accurate by the time seed implantation
takes place [12]. The multiple TRUS imaging sessions could also create a certain
amount of discrepancy between the US images acquired at different times as it is
generally not possible to place the patient and insert the rectal probe in exactly the
same way as before. Furthermore, seed misplacement was hard to avoid because of
shifts in the prostate, tissue deformation and needle flexing. This makes the post
implantation session an absolute necessity to check the actual coverage obtained after
the seed implantation.
Compared with prostate brachytherapy, there is relatively Tittle work done to
date on lung brachytherapy. Much of the work is still at a research stage with ad
ditional interest created by the availability of surgical robotic systems where, in [13]
the accuracy of manual seed implantation is compared to that of the ZEUS robot.
Nonetheless, the accuracy of the current lung brachytherapy procedure has also been
suffering from drawbacks such as the changes in tumor’s size and location between
pre-planning and seed implantation, as well as the inability to compensate for inaccu
rate seed placements [14]. The procedure is further complicated by the more sensitive
area and the need to perform brachytherapy in the presence of motion (respiratory
and cardiac).

1.2

R esearch M otivation

Given some of the drawbacks of the brachytherapy procedure at the current stage,
the motivation behind this research is to reduce the errors in the brachytherapy
procedure with reference to the lung and prostate brachytherapy. As mentioned
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before in section 1.1.2, a seed template is currently used to control the placement of
seeds inside the tumor. However, the template may also be a nuisance in the sense
that the template grid that is overlaid on the tumor in the pre-operative images are
different to the template grid seen during actual implantation, which might lead to
inaccurate dosimetry results; also seed misplacements may occur if a needle is inserted
through the incorrect hole in the template. With the advances in medical robotics,
the elimination of the template can prevent these errors mentioned above, where seeds
can be deposited anywhere inside the tumor from any angle as desired. To this end,
this research is conducted based on the availability of such a robotics set-up, which
is described in more detail in section 4.1.1.2.
In particular, this research consists of two components, which are the pre-planning
or dosimetry planning component, and the intra-operative dynamic dose optimization
(IDDO) component. The first component attempts to provide a means for the online
generation of a dosimetry plan for use in seed implantation, effectively reducing the
time span between dose planning and seed implantation. The IDDO component aims
to compensate for seed misplacements by updating the dosimetry plan dynamically
to ensure that an optimal coverage is achieved at the end of the procedure. Post
implantation evaluation is still required nonetheless, to verify the actual seed locations
against the desired seed locations, i.e. to verify that the desired radiation coverage is
achieved.

1.2.1

Goal of Pre-planning

The goal of the pre-planning component is to generate seed locations to deliver the
prescribed dose to the target volume in on-line mode, in other words, to create the
dosimetry plan in real-time. In doing so, the same images that are used to generate the
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dosimetry plan are also used during the actual implantation of the seeds; meanwhile
the time span between the dosimetry planning step and the seed implantation step is
reduced to a minimum. The pre-planning component essentially combines steps one
and two of the four-step procedure described previously, thus reducing the amount of
error that is present in the current four-step procedure between the intended tumor
coverage of dosimetry planning and the actual tumor coverage at the end of seed
implantation. There are mainly two factors that contribute to this error.
One is imaging errors between dosimetry planning (pre-planning) and seed implan
tation, because dosimetry planning is carried out on the US images obtained during
pre-implant volume study (section 1.1.2), while seed implantation is performed on a
new set of real-time US images obtained in the OR during treatment. Since the im
ages for the pre-planning step (which is taken at pre-implant volume study) and the
seed implantation step are taken at different times and possibly different locations, it
is very important that the patient, and the equipment are positioned in exactly the
same way in both steps in order to obtain identical images in both steps. However,
during seed implantation, it is nearly impossible to duplicate exactly the position of
the patient and equipment from before, even though the angle of the mounting appa
ratus of the probe and the angle of the probe itself are recorded during pre-implant
volume study as mentioned in section 1.1.2. Even the smallest discrepancy between
how the equipment or patient have been placed from one step to the other might lead
to a significant amount of error between the images for pre-planning and seed im
plantation. This will ultimately lead to a discrepancy between the intended coverage
of the tumor which is based on images from pre-implant volume study and the actual
coverage of the tumor which is based on a different set of images.
Another factor is due to the waiting time (usually a few weeks) in the currently
practiced brachytherapy procedure between the off-line dosimetry planning and actual
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seed implantation. The dosimetry plan is created based on the US tumor images
obtained during pre-implant volume study, and the seeds are deposited in the tumor
volume according to this plan during seed implantation. The time elapsed between
pre-planning and seed implantation may have caused a change in the size and shape of
the tumor, and thereby the dosimetry plan for the pre-implant tumor may no longer
be appropriate for the tumor at seed implantation, even if the patient and equipment
have somehow been placed in exactly the same way in both steps.
To this end, the aim of the pre-planning component is to solve these problems by
doing everything ‘on-line’, from pre-implant volume study to creating the dosimetry
plan, which would then be ready to be used for immediate seed implantation. Thus
ideally only one US imaging session would be required, during which time pre-implant
imaging, dosimetry planning, as well as seed implantation (which are the first three
steps in the commonly practiced four-step procedure for brachytherapy) would all
take place, thereby minimizing errors caused by different positioning of the patient or
equipment during a later session; as well as minimizing errors caused by the natural
growth of the tumor itself because the exact same images are used for both pre
planning and seed implantation and that the time elapsed between the steps are very
short. Thus, as long as the seeds are deposited accurately according to the dosimetry
plan, the actual coverage of the tumor at the end of seed implantation will be much
closer to, if not exactly the same as, the intended coverage at pre-planning.

1.2.2

Goal of IDDO

The second component of this research - Intra-operative Dynamic Dose Optimization,
involves performing optimization in real-time in order to compensate for any seed
misplacements.
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As described in section 1.2.1, the seeds must be accurately deposited according
to the pre-plan in order to achieve the intended radiation coverage of the tumor.
Though, as mentioned in section 1.1.2, needles can sometimes be inserted through
the wrong hole in the seed template or the seeds themselves may be deposited at an
incorrect depth. On top of these preventable human errors, there are other errors
that are not preventable which will lead to a different coverage of the tumor volume
as compared to the one from pre-planning. These errors may again be caused by
the difference in the positioning of the patient and/or equipment from pre-implant
imaging to seed implantation as in the case of prostate brachytherapy. As described in
section 1 .1 .2 , the current dosimetry planning software overlays the seed template grid
on top of the US images, and thus the dosimetry plan is created with a pre-defined
position of the seed template. It has been mentioned in section 1.2.1 that during the
seed implantation step, it is difficult to mount the seed template exactly according
to how it was done in pre-implant volume study. However, the template position
from the pre-implant volume study is assumed by the dosimetry planning software
as the template position that is used during seed implantation too. As such, during
seed implantation, it might not be possible to deposit the seeds at their intended
destinations due to a shifted seed template.
To account for this drawback, and therefore to compensate for any seed deviations,
the IDDO component is used to generate a new dosimetry plan in real-time to best
meet the intentions of the dosimetry plan as specified during pre-planning. IDDO can
also compensate for seed misplacements due to tissue shift, needle bending or deflec
tion. The IDDO component is necessary to guarantee that the best possible coverage
can be achieved, thus eliminating the repetition or extension of the brachytherapy
treatment. In the end, a post-implant check-up can be performed to ensure that
adequate dosimetry coverage has been achieved.
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1.3

T h esis C ontrib u tion

As a whole, this thesis improves upon the current LDR brachytherapy method with
particular reference to prostate and lung cancer. In particular, one contribution of
this thesis is to improve the accuracy of the overall procedure by performing dosimetry
planning on-line. In terms of the four-step procedure, this implies that pre-implant
volume study, dosimetry planning, and seed implantation are all performed together,
thus reducing any errors that could be caused by the different positioning of the
patient and/or equipment, or by the natural growth of the tumor, between pre
operative imaging and treatment. In addition, the dosimetry planning in the four-step
procedure is created off-line because it is quite time consuming since it is commonly
done by the radiation oncologist by an educated guess. Achieving on-line dosimetry
planning by this thesis effectively leads to the creation of a more accurate plan in
very little time, which in turn would lead to a more complete and accurate coverage
of the tumor volume.
The other major contribution of this thesis lies in the real-time compensation for
any misplaced seeds during seed implantation, thereby ensuring that an optimal dose
can be delivered to the entire tumor by the end of the procedure. Compensation for
seed misplacement is in fact absent in the currently practiced four-step procedure,
however seed misplacements do occur in the OR as mentioned previously in section
1.1.2. By introducing real-time compensation for seed misplacements, in the event
that seeds are deposited incorrectly or even if the dosimetry plan does not provide a
complete coverage to the tumor volume, new seed locations can be generated on-thefly so to speak to achieve the intended dose so that the final coverage of the tumor
volume would still be satisfactory and the overall procedure would be more successful.
Both of the contributions described above are novel contributions in brachyther-
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apy, and will particularly improve the LDR brachytherapy treatment technique for
prostate cancer and provide a viable approach for dosimetry planning for lung cancer.
Application to the lung and the prostate are of particular interest in this thesis be
cause for North American men, prostate cancer is the most commonly found cancer
and the second leading cause of death from cancer [15, 16], while lung cancer is the
most common cancer found in both genders worldwide [17] and it is the number one
leading cause of death from cancer [15, 16, 17].
Another contribution of this thesis is the use of these algorithms with the aid of
a robotic-assisted brachytherpay set-up (which is described in more detail in section
4.1.1.2) under image-guidance, where seed insertion can be performed from various
angles and there is no restriction of seed separation or discrete'locations because a
template is no longer in place. It is important to develop online dosimetry planning
approaches and also online procedure for correcting the effect of implantation errors as
they have been done in this project so that a more complete coverage of the tumor can
be obtained to take the brachytherapy procedure for the prostate, lung and possibly
other organs, to the next level.

1.4

O rganization o f T h esis

Chapter 2 of this thesis presents an overview of the current research topics on lung and
prostate brachytherapy. The details on the formulation of the optimization problems
for dosimetry planning and seed compensation components are presented in Chapter
3 while the experimental results are described in Chapter 4. Chapter 5 concludes
the thesis by summarizing the achievements of this work, as well as outlining future
research on the topic.
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C h apter 2
B ackgroun d and L iteratu re R ev iew
This chapter presents a review of the work done in this field, specifically on the
development of real-time intra-operative planning for prostate brachytherapy (section
2.1.1). While there is currently not much work in the area of lung brachytherapy,
an overview of some of the recent research work is presented in section 2 . 1.2 to show
that this a promising treatment for lung cancer. Modeling of brachytherapy seeds is
discussed briefly in section 2.2, and section 2.3 presents the parameters involved in
calculating the dose delivered by brachytherapy sources.

2.1

C urrent W ork

In the following, first the development of intra-operative dosimetry for prostate brachyther
apy is described; followed by a description of some of the work in the area for the
development of lung brachytherapy.

2.1.1

P rostate Brachytherapy

Referring back to the dosimetry planning step in the four-step procedure for prostate
brachytherapy from section 1 .1 .2 , it is generally not possible to deliver the exact
amount of desired dose to the target volume while providing precise coverage at
the boundaries of the treatment region, thus the solution to the dosimetry planning
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problem becomes one of finding the ‘optimal’ solution [18]. This section starts with
a brief history on prostate brachytherapy, before introducing the current research on
intra-operative planning for prostate brachytherapy.
2 .1.1.1

B ack grou nd

In 1917, treating prostate cancer using prostate brachytherapy involved inserting
radium needles transperineally [19]. Up to the 1960s, various radioactive substitutive
materials were tried as a replacement for radium in prostate brachytherapy, including
colloidal gold. It is mentioned in [20] that a transrectal ultrasound that was developed
for use in prostate biopsies was extended to the implantation of iodine seeds. With
the improvements in US imaging, the improved visualization of the prostate and
surrounding structures lead to the first major attempt at prostate brachytherapy
using 125I seeds in 1972 at the Memorial Hospital in New York [21]. In this work, the
seeds were implanted by the retropubic approach, which is through a lower abdominal
incision. Another attempt made in 1987 also used the retropubic approach [22]. Poor
long term results were reported in [23] as due to the poor geometrical arrangement
as a result of the implantation method. The US and perineal template combination
insertion method was refined by Ragde and his colleagues in Seattle [24], which was
later taken up across North America. Real-time implantation of permanent source
into the prostate was introduced at the Mount Sinai Medical Center in New York in
1990 [25].
Since then, much research and development have been devoted to the field of
prostate brachytherapy, the focus of which is particularly on real-time implantation
and intra-operative optimized planning. The sections below will describe some com
mercial systems, as well as current research that is trying to achieve real-time im
plantation and intra-operative planning.
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2.1.1.2

Commercially Available Systems

The commercially available systems presented in [12] are the Interplant System (Bur
dette Medical System, Champaign, IL); PIPER (RTek, Pittsford, NY) which is short
for Prostate Implant Planning Engine for Radiotherapy; SPOT (Nucletron Corpora
tion, Veenandaal, Netherlands) which is short for Sonographic Planning for Oncology
Treatment; Strata (Rosses Medical Systems, Columbia, MD); and VariSeed (Varian
Medical Systems, Palo Alto, CA).
The Interplant System uses a built-in optical encoder to register the US images in
real-time against the probe and template positions, thus providing instant feedback of
the probe position within the prostate. Seed positions are estimated from the probe
position and the needle track, so the plan can be updated if required [12 ].
The PIPER system offers automatic segmentation of the prostate, rectum and
urethra on TRUS images, which can all be done in less than 2 minutes [12]. Live TRUS
is used to identify the needle tracks, from which the needle path can be determined.
The seeds are assumed to lie at their pre-planned positions in the z direction, so
that compensations for deviations in the x and y directions can be done through an
iterative process of isodose review, and dosimetry data analysis.
SPOT uses 3D US to identify the needles and seeds as they are implanted into the
prostate volume. However, manual intervention is often required to localize many of
the seeds and needles. The resulting absolute or percentage dosimetry data can be
displayed with respect to the absolute, or percentage prostate volume [26]. In Strata,
the seeds are assumed to have been deposited at their pre-planned locations, based
on needle information extracted from TRUS and sagittal US images [26].
The VariSeed system assumes that the needles run straight and do not deviate [12],
and the tip of the needles are identified using TRUS. As the seeds are inserted, their
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positions are marked on the planning system, and the corresponding isodose curves
are generated. As mentioned in [26], this system does not account for intra-operative
seed motion.
2.1.1.3

Image Guidance & Robot Assisted Approach

In modern prostate brachytherapy, free-hand seed implantation has been replaced by
the image guidance of MRI, TRUS [27], as well as fluoroscopy imaging. The ability of
TRUS in providing real-time localization of the prostate and needles at the same time
has seen TRUS being used as the primary source of image guidance in brachytherapy
procedures nowadays. Due to the inherent noise in US images, segmentation of the
prostate gland is commonly done manually, which is a tedious and time-consuming
process if the planning is to be done intra-operatively. Reference [27] describes a
method where US images are pre-processed to remove noise and increase the contrast,
in order to segment the prostate gland automatically.
A four-step procedure has been proposed in [28, 29], where 3D TRUS guidance
has been used throughout to achieve dynamic intra-operative prostate brachytherapy.
The first step involves the semiautomatic segmentation of the prostate using a Discrete
Dynamic Contour (DDC) model. The segmentation of the prostate is an iterative
process where four points must be selected on an initial slice to start the segmentation
process. The DDC model has been used in a similar fashion to the work in [30, 31, 32],
which involves segmentation of the prostate using the DDC model. In the second
step, the 3D dosimetry planning for the segmented volume is based on geometric
optimization and simulated annealing. To perform dynamic replanning and intra
operative dosimetry evaluation, needles and seeds are located in the 3D TRUS images
in steps three and four, respectively. The accuracy of the overall brachytherapy
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procedure in [29] is further enhanced by the assistance of a robot, where the needle
targeting accuracy has been reported to be 0.79mm ± 0.32mm.
Another method utilizing real-time TRUS guidance for dynamic intra-operative
prostate brachytherapy has been proposed in [33], where the treatment planning
software is supplied with real-time TRUS images. Each seed is identified in real-time
by the dosimetrist with concurrence by the clinician, based on the needle tip that is
visible in the sagittal view. In this work, real-time feedback of the deposited seeds
forces the treatment planning software to update the dosimetry, with regard to the
implanted seeds and seeds that are yet to be implanted. When the dosimetry result
on 90% of the target is showing a difference of more than 5% from the intended dose,
a re-plan is required. The re-plan takes into account the effect ofthe deposited seeds
and generates a new dosimetry plan for the remaining seeds. Reference [33] reports
satisfactory results in terms of dosimetry parameters, because there are no significant
differences between the intra-operative dosimetry and the post-implant evaluation.
Reference [34] describes a technique that allows for accurate seed and needle
placement also by using real-time US feedback. The technique does not require
pre-planning and dynamically implants seeds into the prostate, taking into account
prostate motion during implantation. In this work, the prostate volume is calculated
from the US images in both transverse and longitudinal directions. Without the need
for a pre-plan, the needles are then inserted based on the dosimetry evaluation from
idealized and prior implants. In particular, [34] mentions that 60% to 70% of the
needles will be inserted into the periphery of the gland, while the remaining needles
are inserted into the interior of the gland. The seeds are then deposited using the
Mick applicator. As mentioned in this work, the major advantage is the elimination
of the time-consuming pre-planning. A similar technique has also been described in

[35].
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An iterative algorithm has been described by [36], where one seed is placed at
each step to achieve an optimal coverge of the prostate, using real-time interventional
magnetic resonance (IMR). The use of real-time IMR can provide both geometric
and dosimetric feedback during needle placement. In this work, the position of the
needles are observed before the sources are placed, especially for needles that have
been placed incorrectly. Incorporating this information into the treatment plan, and
thereby evaluating the dose to the entire target volume at each step, the underdosed
regions can then be determined as to where the next seed will be placed. The pre
planned coverage reported in this work suggested that the prescribed dose covered at
least 93% of the tumor; though as much as 13% coverage of the tumor was lost after
updating the plan with real-time needle feedback.
A robotics-based prostate brachytherapy setup has also been developed at CSTAR
(Canadian Surgical Technologies and Advanced Robotics) [37]. Force interaction
between the needle and tissue are used to detect and control the location of needles
and accurate placement of seeds inside the prostate. The same subject is discussed in
a different paper in [38], in which the main focus is put on controlling the trajectory
of the needle after insertion. Reference [38] proposes rotating the needle at particular
locations during insertion in an attempt to insert the needle according to its desired
trajectory. In particular, the developed algorithm is applicable for a period of time
during a prostate brachytherapy procedure when imaging feedback is unavailable.
Although the intention of this work is to improve the accuracy of needle insertion prior
to visulization of the needle tip on the US screen, the authors also plan to integrate
their work with real-time imaging to better control the motions of the needle once
they are near the target.
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2.1.1.4

Image Registration Approach

In [39], both TRUS and fluoroscopy are used to perform real-time dosimetry for
prostate brachytherapy. TRUS and fluoroscopic images are registered using a single
fluoroscopic image of the TRUS probe, edges of the probe are found in the fluoroscopic
image by using an intensity-based edge detector and a least-squares fit. The tip of
the needle, which is a white flash, is manually located in the TRUS image. The seeds
are modelled as line sources, where the x, z coordinates of the seeds are determined
from fluoroscopic images while the y coordinates of the seeds are determined from
TRUS images. Based on the location of the seeds, dosimetry due to the currently
deposited seeds can be calculated, and underdosed regions can be identified, so that
the radiation oncologist can perform interactive planning and update the plan if
necessary.
Reference [40] proposed performing intra-operative dosimetry for prostate brachytherpay by the use of a nonisocentric C-arm, where the fluoroscopic images are registered
to the US images. Fluoroscopy images of intraprostatic sources and fluoroscopy track
ing fiducial (FTRAC) are taken from multiple angles, so that the source positions can
be superimposed onto the US images of the prostate by running a source segmenta
tion algorithm that computes the fluoroscopy angle from the fiducial image. The
source segmentation was carried out by a morphologic top-hat transform, followed
by thresholding and region labeling to obtain the regions that are source-like. Reg
istration of US to fluoroscopy (RUF) is performed twice, once after the placement of
approximately half of the planned seeds, and then after the completion of the place
ment of all planned seeds. During RUF, a set of 4-5 C-arm images is obtained. The
sources are reconstructed in the US space, before they are exported to the treatment
planning system, where the deposited sources can be removed from the original plan
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to generate a ‘residual implant plan’. Based on the ‘residual implant plan’, the physi
cian can modify the remainder of the seeds to optimize the overall plan. This work
presented the results from six patients, in all of which at least 88% of the tumor
volume received 100% of the prescribed dose. The consequence of this however, is an
undesired high dose (> 98% of the prescribed dose) to 30% of the urethra.
Elsewhere, in [41], the dynamic dose optimization relies on the updated structure
volumes by registering images from the Fluoroscopic Frame of Reference (FFR) to
the Ultrasound Frame of Reference (UFR). The FFR is the system of axes imposed
by the C-arm geometry, while the UFR is the system of axes determined by the US
probe and seed template. The contours of the prostate, and other structures are
outlined by the physician in the UFR. In this work, first the coordinates of the seeds
are automatically calculated with reference to the FFR. Then, the images from the
FFR space is fused together with the UFR, which is done by identifying reference
points (lead markers) in both the FFR and the UFR. The reference points are noncoplanar x-ray opaque markers imbedded in the US probe, so that they are visible
in both frames. Generally speaking, five to seven markers are required to minimize
errors. The transformation that allows the superposition of the two sets of markers
effectively defines the translation-rotation transformation between the two systems.
The lead markers are extracted from a grey-level image (fluoroscopic image) of the
implanted seeds. The seeds must also be identified in each image, however separating
a single seed from a cluster of two or more seeds is an apparent difficulty. Lastly, by
verifying the results after registering images from the FFR to the UFR, a decision
can be made regarding whether re-planning is necessary.
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2.1.1.5

Algorithm-based Approach

Reference [42] describes a method for treatment planning using the 1251 or 103Pd
seeds by calculating the dosimetry data in the volume before the placement of each
individual seed, and thus determining the underdosed regions in the tumor and where
the next seeds should be placed. The optimal seed configuration is one that has the
minimum total activity due to all of the implanted seeds. The clinical results showed
an improvement over the older treatment methods.
The algorithm developed by [43] for the purpose of intra-operative real-time plan
ning is based on region of interest (ROI) adjoint functions. The adjoint functions
have been defined as the sensitivity of the average dose in the ROI to a unit-strength
brachytherapy source at any seed postion. Using the ratio of target to critical struc
ture adjoint functions, the seed positions are ranked according to the amount of
radiation delivered to the target ROI versus the critical structure ROIs. Before the
optimization process, this ratio is computed for all seed positions, so that the opti
mization process can select the appropriate seed position according to the computed
ratio values. The main achievement in this work is that the proposed algorithm
is about 1500 times faster than the branch-and-bound Mixed Integer-Programming
(MIP) model.
The work by Alterovitz focuses on using Linear Programming for HDR brachyther
apy, the goal here is also aimed at delivering a desired amount of dose to the target
volume [44]. In this work, it is also stated that the objective function values have
been significantly improved using linear programming than using Simulated Anneal
ing. Due to the nature of the optimization technique, the potential seed locations are
discretized in this work.
In [45], a genetic algorithm for the optimization of prostate implants was carried
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out on an idealized model using 103Pd sources. In this work, the coordinates of the
template grid within the field-of-view of the target volume’s image are encoded into
a fixed-length linear string, where 0 indicates no seed placement and 1 indicates a
seed has been placed. The algorithm presented is based on varying the distributions
of needles and sources. In paticular, the quality of the source distributions has been
expressed in such a way as to reflect dosimetric and clinical considerations, so that an
optimal coverage can be achieved in the end. The results showed improvement over
the implantation of unoptimized implants for the same given target volumes.
Several MIP models have been proposed by [46], where the optimization involved a
number of branch-and-bound strategies. The focus of this work is on two dimensional
prostate contours, where near-optimal seed placements are generated in less than five
minutes on a 333 MHz machine; the extension to the three dimensional case involves
the appropriate interrelation of a sequence of the two dimensional problems.
Lee’s M IP Models
Lee’s optimization approach in solving the dosimetry planning problem in [47] employs
the MIP algorithm. Due to this integer-based approach, the seed space must be
discretized. In this work, the variable Xj is used to record the placement (xj = 1) or
non-placement (Xj = 0) of a seed at point j, where n is the total number of points
available and

Xj

is the vector of the coordinates of point j. Two models are proposed

in [18], the essence of these models is to deliver an optimal dose to the target volume,
while constraining the dose delivered within an upper and lower limit. However, it is
stated in their work that it is generally not possible to satisfy all the constraints.
The first model tries to maximize the number of points that will satisfy Uf, and
Li, by first identifying a maximum feasible subsystem.

is defined as the accepted

upper bound of the prescribed dose, usually at more than 100%, while L 5 is defined
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as accepted lower bound of the prescribed dose, usually at less than 100%. The
constraints of this model are given below in Eq. (2.1),
n
£ OdIF - X j||)xj + Np(l - v%) > Lb
(2.1)

n

£ D(llp - *¿11)*) - M p(1~«p)iUb

j= 1

where P is a vector corresponding to the coordinates of the point of interest, so then
for x j = 1, D(\\P —X j ||) refers to the dose at point P due to the j th seed at location
X j. In this equation, vp and vp have values of 0 or 1, and Mp and Np are positive
constants. The goal of this model is to deliver a final dose that lies within the bounds
Lfj and t/&, thus forcing vp and vp to be 1. The goal is stated as follows,

Maximize ^ 2 ( a pvp + /3pvp + n/pvp U)

(2.2)

P

In Eq. (2.2), ap and j3p are weighting factors to reflect that certain points might be
more critical to achieve the target dose level than others. vp = 1 implies that the
dose at point p is > Z^, though the dose might even be greater than the imposed
upper limit; on the other hand, vp = 0 implies that the dose is less than L^, and
obviously less than

too. vp = \ represents that the dose at point p is < [/¿, but

might even be smaller than L^\ whereas if vp is equal to 0, this would mean that
the dose at point p is larger than U^, in the meantime larger than

too. A value

of 0 for vp u indicates that the dose at point p is either more than the upper limit or
less than the lower limit, but if vp u is equal to 1 , then the dose at point p is within
the limits set by

and L&. Thus it would be desirable to have vp u = 1, for this

condition would mean that vp and vp also have a value of 1 .
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The second model proposed by Lee in [18] attempts to minimize a weighted sum
of the deviations, by calculating the amount of deviation from the desired target at
each individual point in the tumor volume. The constraints for this model are similar
to those in the first model and are given in Eq. (2.3),

' £ , D ( \ \ P - X j \\)xj + y l ; > L b
(2.3)

n

'£,D(1lP - X j \\)xj -y V < U b
j =1
where yfe and

are positive continuous variables that represent the deviations from

the lower limit and upper limit respectively. They are used as constraints in mini
mizing the weighted objective function in Eq. (2.4):

Minimize

+ PpVp )

(2.4)

P

Lee’s work proposes using the conformity index (a ratio of total volume enclosed
by the isodose surface to the target volume enclosed by the same surface) and the
coverage index (ratio of target volume enclosed by the isodose surface to the total
target volume) to aid the assessment of the quality of their results. Section 4.3.4
presents a comparison of the dosimetry planning results between Lee’s work and the
algorithm proposed by this thesis.

2.1.2

Lung Brachytherapy

As for lung brachytherapy, there has been relatively little work done on dosimetry
planning. Even for the equipment used in lung brachytherapy, adaptation from the
prostate brachytherapy environment is difficult not only due to limited access because
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of the presence of the ribcage, but also more constraints need to be met for lung
brachytherapy procedures since there are vital organs in close proximity and there is
significant motion due to respiration and heart beat. Trejos et al. (from CSTAR) have
developed devices, integrated systems and a test-bed for minimally invasive robotassisted lung brachytherapy [48, 49, 50]. In [48], they discussed issues that affect the
precision in seed deployment, such as the difficulty in the penetration of the needle
to the correct destination due to obstacles as a result of anatomical structures and
organs. Also the instability of the equipment while dropping the seeds might lead to
seed misplacements. To account for these factors, and to reduce exposure to radiation
for healthcare personnel during a brachytherapy session, the constructed device from
[49] has been implemented in an integrated system along with commercially available
dosimetry planning software to perform minimally invasive lung brachytherapy under
the guidance of US imaging. Moreover in [50], the dosimetric results of the MIRA
(Minimally Invasive Robot-Assisted) V system are assessed against various radiation
parameters and the in vitro results obtained are acceptable.
Also, [51] reported a procedure for lung brachytherapy where 125I seeds are sewn
into resection margins for T1 and T2 stage lung tumors. Lung tumor staging is
explained in more detail in Appendix A. In this study, the 125I sutures are secured
in a nonabsorbable mesh, which is then pushed through the endoscope and secured
in a ‘tent-like’ fasion over the resection margins. This method is especially beneficial
to patients with small T1 or T2 stage lung tumors who are unfit for lobectomy
or pneumonectomy due to an inadequate pulmonary reserve. Experimentally, this
procedure has been performed on two separate lobes in the right chest cavity of a pig
with the help of the da Vinci robotic system. The seeds are sewn in place using either
the ‘looping’ technique or the ‘longitudinal’ technique [51]. Reference [51] emphasizes
that with the advent of robotic technology, new options for the treatment of lung
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cancer, such as the one that they proposed, may improve and overcome technical
difficulties of instrumental manipulations in the narrow chest cavity.
In addition to the above technique, [9] also discussed how to physically implant
125I seeds to cover the volume of disease in the lung, this procedure is called volume
implant. Though the results of volume implant show inferior results as compared to
surgery, at least it is an option to treat patients who cannot undergo any surgical
resection.

2.2

M od elin g B rachyth erap y Seeds

The cylindrical nature of the brachytherapy seeds induces an anisotropic dose dis
tribution around an individual seed, forcing the correct modeling of the seeds to be
an important aspect in improving the overall accuracy of LDR brachytherapy. The
anisotropicity is due to extra attenuation by greater length of material on the long axis
of the source, which results in a higher dose rate in the transverse axis as compared
to the long axis.
A study carried out by [52] examines the dose distribution of the 6711 model of
125I in 2D space indicates that at a distance r from the center of the seed, the dose
varies with angle 9, which is the angle relative to the seed’s long axis. The study also
presentes an empirical expression that approximated the measured results, since the
r-dependent dose distributions are different at different values of 9.
The dose distribution of 125I in 3D space was studied by [53] using a point source
distribution formula by Berger, which neglected the dose deviation from the exact
dose at distances less than 0.5cm. In this work, the radiation in 3D space has been
calculated and measured, and they found that there is a 5% difference between the
two results at an angle perpendicular to the seed’s axis. The formula used determines
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the 3D dose distribution at any point of interest with a 6% uncertainty. The work
in [53] stated that a complete mathematical function describing the entire 3D space
dose distribution in tissue is required if the precise 3D distribution is to be calculated.

2.3

D o se C alculation

Guidelines supplied by [5] from the American Association of Physicists in Medicine
(AAPM) provided detailed information on brachytherapy seed types, isotope radioac
tivity, dose rate calculation and suggested clinical dose. The work described in this
thesis follows the recommendations of [5] and uses 144Gy as the suggested 100% dose.
To calculate the dose at a particular point, the dose rate formula from [5] is used.
The dose rate, D{r), due to a point source at r units away is given by the formula
below:
D(r) = Sk • A • g(r) ■G(r, 0) • <Pan(r)
In this equation,

(2.5)

is the initial activity of the source, A is the dose rate constant,

g(r) is the radial dose function in the transverse axis of the seed, G(r, O) is the
geometry factor for the seed source, and $ an(r) is the anisotropy correction factor.
The details for these parameters are given in Appendix B.
Prior to converting dose rate to dose (D(r)), Tiy2 of the source is required to
calculate the meanlife of the radionuclide, r,
_ Tl/2
T ~ ln{2)
A value of 1426 hours is used for

/2

as mentioned in section 1.1.1.1. From here, the
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dose at any point is given by 2.7 as in [7],

D(r,Q) = D (r ,6 ,t0) - t ■ku

(2.7)

where ku is a conversion factor in hours (h), and in this case, since the half-life is
already expressed in h, the value of ku is 1 .
The details on the formulation of the optimization problems for dosimetry plan
ning and dynamic dose optimization are explained in the next chapter.
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C h apter 3
O p tim iza tio n -b ased P la n n in g A pproach
This chapter starts with an overview of the proposed solution in section 3.1. Then the
details on the formulation of the dosimetry planning and IDDO optimization prob
lems are presented. In particular, an in-depth description of the dosimetry planning
algorithm is given in section 3.2 while section 3.3 presents the details of the IDDO
algorithm.

3.1

P ro p o sed Solu tion

In order to achieve the goals stated in section 1.2, two optimization problems are
formulated and solved for each of the dosimetry planning and IDDO components.
In general, the optimization problems are constrained by the condition that the dose
at each and every point of interest throughout the volume has to be within the
imposed bounds U&and L&. The purpose of the governing objective function is to
deliver the desired amount of dose to all points under consideration.
Different from the results of Lee’s work which produced seed locations specified in
discrete-space, the locations of the seeds produced by the proposed algorithms in this
thesis are to be specified in continous-space, implying that there are no limitations
on the final locations of the seeds so long as they are all within the volume of the
tumor. The actual tumor volume is not defined in the continuous-space but has been
discretized to make the problem more tractable, for a tumor volume defined in the
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continuous-space would be composed of an infinite number of points, and it would not
be possible to consider and satisfy all these points for dosimetry. The discretization
of the tumor volume is based on the tumor shape, and since no assumption has been
made regarding the shape and size of the tumor, this guarantees that the optimization
problem is applicable to all tumors.
The approach undertaken in this thesis is to optimize the overall dose that would
be delivered to the target tumor, in such a way that the sum of rewards would be
maximized while the sum of penalties would be minimized. A rewardcorresponds to
a point in the target volume that isfeasible, i.e., satisfies the upper and lower limits
of the prescribed dose; whereas a penalty corresponds to an infeasible point in the
target, i.e., one that receives a dose that is more than the upper'limit or less than
the lower limit of the prescribed dose. Essentially, maximizing the sum of rewards is
equivalent to minimizing the sum of penalties. So the objective of the optimization
can be stated as either Eq. (3.1a) or Eq. (3.1b) below:

Maximize E(r) | L^ < D(r) < Uf,
Minimize E(r) | D{r) < L

or, D(r) > £/&

(3.1a)
(3.1b)

Here, r represents all points found in the tumor volume and D(r) represents the dose
present at the particular point, r.

3.2

P re-p lan n in g A lgorith m D escrip tion

This section describes the formulation of the optimization problem for dosimetry
planning. The problem description is further broken down into three subsections,
section 3.2.1 looks at how the problem is formulated in 3D space; section 3.2.2 explains
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Figure 3.1: Flowchart for 3D.Optimization
how the 3D problem is broken down into a series of 2D problems, which are then solved
one by one using an optimization routine. The details of this optimization routine
including the parameters involved are explained in section 3.2.3. The overall algorithm
is given the name DOPAL, which stands for DOsimetry Preplanning ALgorithm.

3.2.1

Pre-planning 3D Problem Formulation

Figure 3.1 shows the basic steps involved in the 3D.Optimization algorithm. The
following will examine these steps in more detail.
The target tumor’s 3D volume information is the first thing that is required to
begin the pre-planning process using the proposed algorithm. Specifically, the algo
rithm is to be provided a collection of points that describe the contour of the volume,
which trace out a mesh of the actual target as seen in 3D space. Section 4.1.2 explains
how to obtain the contour of ex vivo tumors, which must be done manually.
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Figure 3.2: Cross-sectional image of segmented prostate volume
Then the volume contour is segmented into a number of slices with equal separa
tion <L/i between all slices. There is no strict limitation on the value chosen for d_/i;
however better results are generally obtained when an approximate value of 0.50cm
or less is selected. Figure 3.2 shows a cross-sectional image of a segmented prostate
volume with all the slices, the separation shown here is 0.50cm.
Upon segmentation, the contour of each slice is to be interpolated to ensure that
there is a sufficient number of points describing each slice so that a proper dose can be
delivered to the entire slice. The reason for this is that the objective functions in Eq.
(3.9) and Eq. (3.11) have no knowledge of the shape of the slice itself, so the objective
functions are only concerned with delivering the desired dose to the shape described
by the available contour points. From the algorithm’s point of view the target volume
appears as a collection of points instead of a shape with surfaces or edges, so a circle
described by 4 points might be misinterpreted by the algorithm as a square. As a
result, when the contour points appear quite sparse due to the contour being described
by an insufficient number of points, the outcome of the optimization algorithm for
such a contour will only deliver dose to the few contour points present, leaving behind
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undosed areas in between the contour points. To prevent such misinterpretation from
happening, the number of points defining the contour are interpolated to have at
least 50 points. This value was chosen after numerous experimental evaluations. The
same is done for all apparent contours on a slice, which may include the target region
contour, as well as the forbidden contour. As in the case for a prostate tumor, there
would be two contours present on every slice of the target volume, where one contour
is for the prostate itself (i.e. target region contour), and the other contour is for the
urethra (i.e. forbidden region contour). (A more detailed description on target and
forbidden regions can be found in section 3.2.2)
After ensuring that the contours of all slices have a sufficient number of points, the
Center Of Mass (COM) of each contour is calculated and provided to the optimization
routine as a starting temporary seed, tempseed. The coordinates of the COM for a
contour with n points are calculated based on the following formula,
n

^ 2 miXi
COMx = ^ ------

(3.2a)

i=0
n

^ m iV i
COMy = ^ ------

(3.2b)

J 2 mi
i=0

where

is the mass of point i and X{ and m are the x and y coordinates of point i

respectively. In using the above formulas, each contour is assumed to have a uniform
weight distribution, which implies that the value of nrii is 1 for each coordinate.
Prior to invoking the DOPAL algorithm, the user is required to select values for U
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and Lf,. In the case of a prostate tumor, the user may specify

and

values for the

target volume as 150% and 100% of the prescribed dose respectively; whereas for the
urethra, the Uf, and L^ values may be specified as 120% and 100% of the prescribed
dose [47]. For this reason, the values for U^ and L& were not hard-coded, to provide
flexibility for the different values they may take as required by different types of
tumor. These user-specified

and

values, along with the contour information of

the 3D volume, as well as the contour information of the 2D slice of interest, are used
as inputs to formulate the 2D optimization problem. The resulting output is a set of
optimal seeds located on the current slice of interest.
A 2D optimization problem must be formulated for every slice from the current
target volume, and the resulting volume-wise optimal seeds (DOPAL-2Dseeds) from
each particular slice are stored and the corresponding volume-wise violation amount
is calculated accordingly. A violation occurs when the dose delivered to point i, D(i),
is greater than the accepted upper limited (D(i) > [/¿) which corresponds to an
overdose, or less than the accepted lower limit (D(i) <

which corresponds to an

underdose. The violation amount (vio-amt) is defined below as the summation of the
amount of overdose (overdose-amt) and underdose (underdose-amt), taken from each
and all contour points. Thus for a volume with n slices, where each slice is defined
by, say 50 contour points, overdose-amt, underdose-amt and vio-amt are given by:

underdose-amt =

n 50
£ ( £ [ £ 6k=0 2=0
n 50

D(i)]) for D(i) < Lb

overdose-amt = £ ( £ [ £ > ( > ) - Ut}) for D(i) > Ub
k=0 2=0
vio-amt = underdose-amt + overdose-amt
This volume-wise slice-by-slice optimization is repeated in this manner until no
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further change is seen, at which time the output have converged to a solution. Even
in the case when the solution does not converge, this algorithm is still terminated
after a maximum number of iterations denoted by a value that is set by the user prior
to executing the algorithm.

3.2.2

Pre-planning 2D Problem Formulation

This section of the algorithm is invoked for every slice contour that is a segment of
the tumor volume, the goal here is to add more seeds to the slice of interest if it helps
to provide a better dosimetry plan overall. Figure 3.3 illustrates the steps involved
in the algorithm, which are discussed below in detail.
In some cases it appears better to leave the slice void of any seeds. As such,
each slice invokes the optimization routine with no seeds present on this particular
slice, but instead provides the seeds found on all other slices, which is referred to
as seeds-otherslices. Based on seeds-otherslices, a vio-amt is calculated and stored
so that it can be compared later against the new vio-amt due to new-DOPAL.seeds.
new.DOPALseeds is a matrix containing the set of seeds from the previous execution
of the optimization routine, plus one new entry of ‘modified temp.seed'. The values
of the ‘modified temp-seed' and the reason for this modification are explained shortly.
When this algorithm {2D-Optimization) is executed, it assumes that other than
the current slice of interest, there are seeds on all other slices throughout the volume.
However on the first call of 2D-Optimization of the l 5i slice, this would not be the
case since the entire volume would be empty of seeds. Nevertheless, the algorithm
starts with the assumption that every contour point of the slice is either underdosed
or overdosed, thus the total number of violation points of the current slice, which is
defined as min-vio, is assigned a value that is equal to the total number of contour
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Figure 3.3: Flowchart for 2D-Optimization
points on the current slice. For instance, a slice contour having a total of 50 points
would imply an initial number of 50 violation points, as in Eq. (3.4):

m in-vio — 50

(3.4)
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The current dosimetry plan - which would be empty and contains no seeds, is stored
as the optimal plan DOPAL.2Dseeds. In other words, at the start of 2D.Optimization
for each slice, DOPAL.2Dseeds is an empty matrix.
To continue with the 2D problem formulation, a new violation value named ‘viola
tion points’ (vio.pts) has to be calculated, which is due to the presence of temp.seed.
The matrix temp.seed contains the coordinates of one seed only, which corresponds
to the location of the COM. The x and y coordinates of the temp.se.ed can be ob
tained using the COM formulas from Eq. (3.2a) and Eq. (3.2b). The 2-coordinate
of tempseed does not need to be calculated because it is supposed to be the same as
the z-coordinate of the contour of the current slice, since temp.seed is to be added
only to the current slice of interest in an attempt to reduce the number of contour
points that are less than the lower limit or greater than the upper limit.
As the optimization process continues, a temp.seed is added to new.DOPAL.seeds
whenever 2D.Optimization requests that a seed is to be added. To determine if a seed
should be added or removed, 2D.Optimization keeps track of the number of under
dosed points as well as the number of overdosed points. By comparing the two values,
a decision can be made as to whether a seed should be added to new.DOPAL.seeds
or removed from new.DOPAL.seeds. Intuitively, if there are more overdosed points
than underdosed points, then seeds should be removed, and vice versa.
If seed removal is required, then a random seed is removed from new.DOPAL.seeds.
If new.DOPAL.seeds is already empty, meaning that any seed addition would only
cause more overdose, then DOPAL.2Dseeds is sent back to 3D.Optimization as an
empty matrix and 3D.Optimization moves onto the next slice in the volume.
The calculation of vio.pts takes into account the effects of seeds from all slices in
the volume, including the seeds from the current slice of interest, and tracks the total
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number of contour points that are overdosed (> U5) or underdosed (< Lb).
viojpts =
such that

(3-5)

Dose(i) > Ub, or Dose(i) < L 5
vio.pts is calculated on each run of the optimization routine, and if this new vio
lation is strictly less than the initial miri-vio amount, meaning that one or more
contour points are now dosed properly, then min.vio is overwritten by vio.pts and
DOPAL.2Dseeds is updated to the values of new.DOPAL.seeds. In the event that
new-D OPAL .seeds does not reduce the total number of violation points, neither
miri-vio nor DOPAL.2Dseeds gets modified.
The most desirable outcome is having vio-pts equal to 0, which means that the
value of the objective function of the minimization optimization routine is at its
absolute minimum or is equal to zero, and that each and every contour point i is
within the desirable range of the accepted dose such that,

Vi, Lf, < Dose(i) < Ub

(3.6)

When this happens, the optimization process is terminated and the most recent
new.D OPAL .seeds replaces DOPAL.2Dseeds, and is sent back to the 3D.Optimization
algorithm for the 3D problem from the previous section.
It is possible that a target contour may never receive a perfect dose to all its
points, implying that the value of the objective function may never reach an abso
lute minimum, therefore it is necessary to make sure that the optimization does not
get stuck in a loop by using a counter variable named run.num. The optimization
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process is allowed to iterate for a total of 18 times, a number which has been verified
experimentally as being sufficiently large to produce satisfactory results. If the num
ber of iterations exceeds run.num, meaning that the optimization process has not
produced a dosimetry plan with a lower vio.pts than the current min.vio, the process
is terminated and the currently stored DOPAL.2Dseeds (which may or may not be
the most recent result but is the result that produced the lowest vio.pts) is returned
to 3D.Optimization as the output of the optimization.
Care must be exercised in storing and updating the values in new.DOPAL.seeds.
For instance, if new.DOPAL.seeds consists of only 1 seed, (which was taken from
temp-seed) and is placed outside of the target volume, the seed is deemed unusable and
would get removed, therefore making the DOPAL.2Dseeds variable empty. On the
next consecutive iteration of 2D.Optimization, the same temp.seed is again added to
and then removed from new.DOPAL.seeds, thus forcing the algorithm in to an infinite
loop. The same scenario may also occur if the latest addition to new.DOPAL.seeds
always produces a local minimum as a solution to the optimization problem, forcing all
new seed additions to that particular solution. To prevent the above from happening,
temp.seed is modified prior to every iteration by + 1 in the x direction and —1 in the
y direciton. By doing this, the latest addition to new.DOPAL.seeds is different from
the one that was added in the previous iteration. Using different initial seed locations
on every iteration prevents the optimization routine from producing similar solutions,
especially if the one produced is not valid. Also, using all different values of temp.seed
in new.DOPAL.seeds allows maximum exploration of the entire seed domain.
The boundary of this domain is the boundary of the solution to this optimization
problem, and is essentially denoted by the bounds for the location of all potential
seeds. The ¿-direction bound for a seed is restricted to the value of the ¿-coordinate
of the contour of the current slice, in the same way that the ¿-coordinate of temp.seed
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Figure 3.4: Figure illustrating 3 seeds having identical z-coordinate values
was restricted as well. In other words, the result of running the optimization routine
on every slice produces a set of seeds that have identical z-coordinate values, because
they are all on the same slice. As a result, bounds only have to be specified in the x
and y directions to control the location of the seeds.
Figure 3.4 shows a volume with 3 slices where there are 3 seeds on each slice.
Assume that seeds Si, S2 and S3 (Seed 1, Seed 2 and Seed 3 in Fig. 3.4) are the
elements of DOPAL-2Dseeds (which is the output of 2D-Optimization). It is clear that
the values of the x and y coordinates for all 3 seeds are different but the z-coordinate
value for all three seeds are identical. Furthermore, the seeds from 2D-Optimization
are required to fall inside the target contour defined by the x and y coordinate values
of the contour, because it makes no sense for a seed to be deposited outside of the
tumor volume.
The bounds for each slice can be approximated by a rectangular region, since the
contour of a slice is assumed to be in the shape of a random polygon. The respective
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Figure 3.5: Bounds Sx and Sy for one slice in the shape of a random polygon
bounds Sx and Sy in the x and y directions are given as follows,

Sx e [min(Px), max(Px)\
(3.7)
Sy e [min(Py), max(Py)\
where Px and Py are the collection of the x and y coordinates of the points that
describe the slice contour. In Fig. 3.5, the contour is described by Px and Py, and
Sx and Sy form the rectangular bound that defines the potential location of all seeds
on this slice. As can be seen from this figure, the bounds are not the exact shape
of the contour and include space outside of the contour that are not usable as seed
locations. For this reason, the location of each seed still needs to be verified to make
sure that it is in fact inside the contour.
For a target contour that encloses a forbidden contour, e.g., a slice from the
prostate tumor volume, the single rectangular bound from Fig. 3.5 is then further
divided up into four smaller rectangular bounds, which is illustrated by Fig. 3.6.
In Fig. 3.6(c), the 4 smaller rectangular bounds are overlaid on top of the planar
view of a simplified prostate contour in the shape of a donut, where the inside circle
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is a representation of the urethra and the outside circle is a representation of the
prostate. The equations for the four rectangular bounds are given in Eq. (3.8), where
Sxi indicates the bounds in the x direction for a seed in the l si region; likewise Sy3
indicates the y-axis bounds for a seed in the 3rd region.
Sx 1 e [min(PX0), min(Pxi)\
Syi e [min(Pyo), max(Pyo)]
S x 2 e [min(Px0), max(PX0)\
Sv2 e [m a x ( P v i ),

m a x ( P y o )]

(3.8)

Sx 3 e [max(Pxi), max(PX0)\
Sys e [min(Py0), max(Py0)\
S x4 t [min(Pxo), max(PXo)]
S y4 e [min(Pyo), min(Pyi)]
In Eq. (3.8), Pxo and Py0 are the respective values of the x and y-coordinate that
describe the outside contour, which corresponds to the target region; while Pxi and Py{
are the respective values of the x and y-coordinate that describe the inside contour,
which corresponds to the forbidden region. The essence in employing this approach
is to try and avoid placing seeds in or near the forbidden contour. Evident in Fig.
3.6(c), the four rectangular bounds combine together to cover up the majority of the
target region, but cover no part of the forbidden region at all. When these bounds
are used to control the placement of a new seed, the forbidden region is effectively
avoided.
One drawback here is that there is a certain amount of space included in the
bounds that in fact belong to neither the target region nor the forbidden region. To
account for this inclusion of unusable space, the location of each of the optimized
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(a) Bounds for regions 1 and 3

(b) Bounds for regions 2 and 4

(c) All four bounds overlaid on top of sim
plified prostate contour
Figure 3.6: Boundaries of the 4 regions for seed placement
entries in new-DOPALseeds must be verified to ensure that none of the seeds are
outside of the target. If a seed has been found to lie outside of the target region, i.e.
outside of the contour itself, it is removed from the new-DOPALseeds matrix and
the value of temp.seed is modified like previously mentioned. So that when temp.seed
is added to new.DOAPLseeds on the next iteration, the new optimizatoin based on
the updated new-DOPALseeds will not run into the same problem.
These bounds are especially useful in dosimetry planning for prostate cancer,
where it is crucial to try and avoid delivering dose to the urethra, which runs through
the center of the prostate. The urethra thus becomes the ‘forbidden region’, and the
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Figure 3.7: Bounds on a tumor of elongated shape
surface of the urethra becomes the inside boundary of the ‘target region’ so it would
get protected from being overdosed. The actual ‘target volume’ of the prostate tumor
is therefore defined by two sets of contour points. In the case of the lung, because of
the significantly greater complexity in the thorax and the current state of the robotic
lung brachytherapy project, ‘forbidden regions’ in the lung (which could be quite
complex) were not considered in this initial study. This problem will be addressed in
depth in a more detailed study in the future.
When the method mentioned above is applied to a tumor that is more elongated
than usual, the portion of the tumor covered by the bounds is shown in Fig. 3.7.
It can be seen from this figure that there is also a certain amount of unusable space
being covered by the bounds. The surface area of an ellipse with a major axis of
radius, a, and a minor axis of radius, b, is given by

SA of Ellipse = 7t ■a ■b

while the overall surface area of the bounds can be calculated as 2a x 2b. Ignoring
the bounds around the forbidden region, the unusable space around the target region
is 4ab —nab = ab(4 — n). The unusable space around the target region for a regular
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circular shape with radius r is, 4r 2 —nr 2 = r 2(4 —n). It can be shown from the
above that as both a and b become increasingly bigger, the amount of unusable space
in an elongated tumor becomes larger than that of the circular tumor. Such an
exaggerated shape is of no particular concern to prostate or lung tumors at this time;
nevertheless there is still a method that corrects for this should it occur. The trick is
to break down the four rectangular bounds into ever smaller rectangular bounds. The
smaller the bounds are, the more accurately they approximate the actual elongated
shape. The disadvantage in employing such an approach is that there are more
computations required to figure out the exact parameters that define these smaller
bounds. Though, the improved accuracy in the resulting dosimetry plan may be worth
the effort. In addition, this correcting method would also improve the accuracy of
the shape-approximation for a general circular tumor too.
Once all the parameters have been obtained, i.e., contour information of the cur
rent slice, contour information of the present volume which is composed of all slices
from the 1 st to the current slice, the set of temporary seeds to be optimized, Uf, and
Lfr values, as well as the xyz bounds for potential seed locations, the optimization
routine ‘fmincon’ is ready to be invoked to solve the problem at hand.

3.2.3

Pre-planning’s

<
‘f m i n c o n ' >

‘fmincon' is the constrained minimization routine from MATLAB’s optimization tool
box. This particular routine was selected because it offers the option to minimize the
objective function subject to a set of constraints. Figure 3.8 is an illustration of
how ‘fmincon’ has been used by 2D.Optimization to solve the dosimetry planning
problem.
The objective function requires the following parameters as its input,
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Figure 3.8: Flowchart for ‘fmincorì
• Current slice seeds (curseeds), which is equivalent to new-DOPALseeds
• Seeds from other slices (seeds.otherslices)
• Volume contour (voLcontour), which is made up of all slices prior to and in
cluding the current slice
• Ub and Lb
• Desired % dose (desd.goal)
• z value of the current slice (z.val)
As for the optimization constraint, the required input parameters are as follows,
• Current slice seeds (curseeds), which is equivalent to new.DOPALseeds
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• Seeds form other slices (seeds.otherslices)
• Inside contour of the current slice (inner.cont)
• Outside contour of the current slice (outer.cont)
• z value of the current slice (z-val)
The objective of the optimization is to ensure that as many contour points would
receive a dose that is no less than the imposed Lb and no more than the imposed Ub as
possible, which is in fact a maximization process. The objective function (O bjjn) for
maximization must be modified to fit the requirements of the minimization routine fmincon. Essentially, the solution to the minimum of a negated objective function is
equivalent to the solution of maximizing that same objective function. In any case,
the objective function is mathematically stated below:

53(0» I Vi, * e (Px , Py), where Lb < D(i) < Ub

(3.9)

where D(i) is the total amount of dose present at point i. Since 'fmincon' is invoked by
2D-Optimization for every slice of the contour volume, and because 2D-Optimization
is an iterative process where each successive optimization includes the contours from
all previous iterations, then Px and Py are coordinates that describe the volume which
is made up of all slices from the l si slice to the current slice. In words, Eq. (3.9)
states that for the contour described by Px and Py (which is the collection of points
from the first point on the first contour slice to the last point on the current contour
slice), the dose at every point i is desired to be > Lb and < Ub at the same time.
References [18, 54] stated that the total dose at a particular contour point can be
approximated as the summation of dose from all available seeds. Mathematically, the
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approximation of the dose at point Pq can t>e expressed as:

¿ B ( ||P o - S J )
¿=0

(3.10)

In this equation, D (r) denotes the dose contribution of a seed to a point at a distance
of r units, || • || denotes the Euclidean norm, and

is the vector of the coordinates

of seed i of a total of n seeds. Equation (3.10) says that, the total dose apparent at
point Pq is the summation due to the dose from each of the seeds from S q to Sn. The
dose of each seed, as stated in [18, 54], is based on the Euclidean distance between
the point of interest (Pg) and the location of the seed {Si), where the seed itself can
be approximated as a point source. Specific to the work in this thesis, the irradiation
of a single seed is approximated using the point source formula provided by [5], which
was given in Eq. (2.5).
In the objective function stated in Eq. (3.9), the total amount of dose, D(i), at
each point is calculated using Eq. (3.10). So the total dose is the summation of dose
contributions from all seeds in the volume, essentially this is the summation of the
dose contributions from seeds-otherslices, and the dose contributions from cur.seeds.
Therefore, even though the dose calculation is performed in a 2D setting, it still takes
into consideration the dose contributions within the 3D volume.
It is worthwhile to note here that voLcontour was divided up into the outside
volume contour (outer.cont) representing the target volume, and the inside volume
contour (inner.cont) representing the forbidden volume. Should there be no need
for a forbidden region (such is the case of lung tumors at the current stage), then
inner-cont is an empty matrix that does not affect the outcome of the optimization.
Ub and Li values may be specified differently for each set of contour, thus effectively
controlling the amount of dose that can be delivered to different volumes.

56
Furthermore, the objective function attempts to minimize the total dose deviation
at all points on the contour from desd-goal (which may be 100% of the prescribed
dose), using a least squares method, the mathematical expression is given below:

Minimize {^[£>(z) —desd-goal]2}, where i e (Px , Py)
i

(3.11)

Here, desd-goal may be set to different values for the target and the forbidden volumes
to achieve the respective desired dose.
The exact value of the desired dose at point j, D (j), is specified by the optimiza
tion constraints (OpLCons), given below:
Vi e [0, n]
(3.12)
D(j) = Desired % Dose
Different to the objective function, the optimization constraints are applied to the
current slice only, where n can be interpreted as 50 to represent the number of points
defining the contour of a slice. Then, Eq. (3.12) states that for all points on the
current contour, the intention is to deliver the desired amount of dose to each and
every one of them. The only complication here is that constraints for the inside and
outside contours need to be specified separately, because the urethra (e.g. forbidden
region) and the prostate (e.g. target region) have different dose bounds [47]. To
maximize the amount of prescribed dose delivered to the target region, the algorithm
in [47] incorporates a conformity index on the target region. To achieve the same
goal, the algorithm proposed in this thesis simply specifies a different desd-goal for
each of the inside and outside contours. For simplicity, the variable desd-goal for all
the slice contours in the target region are given identical values. Similarly, the same
value of desd-goal is used for all slices of the forbidden region.
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One possible, although invalid, solution to the optimization problem is having
multiple sources at the exact same location to achieve the desired overall cover
age of the entire tumor volume. This was mentioned before in the previous section
and the prevention method was to use a modified tempseed value for each entry in
new.DOPALseeds. Another constraint (Eq. (3.13)) is used to control the spacing
between adjacent seeds and to further emphasize the importance in preventing this
undesirable outcome. Even though a solution consisting of say 10 seeds at the exact
same location can still produce a complete coverage to the entire tumor volume, in
which the seeds assume a point source approximation, it is physically impossible to
place multiple seeds at the exact same location due to the actual size and shape of
the brachytherapy seeds. Thence, the equation below is used to specify the minimum
allowable distance k between two adjacent seeds,

||Sj+l —5j|| > k, for Si e S~Xy

where

Sj

and

Sj+ \

are available seeds in the matrix

S xy

(3.13)

and || • || is the Euclidean

norm. Equation (3.13) basically says that for all neighboring seeds on the same slice,
the minimum separation between any two seeds must be more than k units.
The results obtained from ‘fmincon’ is sent back to the 2D-Optimization algorithm
where the seed locations are checked and verified again to make sure that all seeds are
inside the target region but outside the forbidden region if applicable. The algorithm
then returns to the start of the 3D-Optimization algorithm and once again the number
of violation points is checked and the above procedure is repeated until covergence is
obtained.
The solution is said to have converged if there are 0 vio-pts in the volume, implying
that each and every contour point is within the accepted upper and lower limits

58

(a) Iteration vs. vio-pts graph of a convergent solution

(b) Iteration vs. vio-pts graph of a nonconvergent solution

Figure 3.9: Graphs showing convergent and non-convergent solutions of DOPAL
of the prescribed dose, at which time both 2D-Optimization and 3D-Optimization
algorithms are terminated immediately because an optimal solution is found (Fig.
3.9(a)).
In the case when convergence is not achieved, two conditions are in place to
make sure that a most optimal solution is produced and that the algorithms do
not run indefinitely. The first condition is that the user can specify the maximum
number of times the 3D-Optimization algorithm should iterate, so that the total
number of executions of the 3D-Optimization algorithm cannot be more than this
value regardless of whether the solution converged or not. The second termination
condition deals with the case when a sub-optimal solution is found for a problem where
the globally-optimal solution may not even exist. To do this, for a volume that has n
slices, when a seed configuration has been found that produces a minimum number
of violation points (not necessarily 0), the 3D-Optimization algorithm is allowed to
iterate for an extra n • 2 number of times. During this time, the 3D-Optimization

59
algorithm is terminated if and only if none of the new seed configurations produces a
lower number of violation points. This is illustrated in Fig. 3.9(b), which was obtained
using a sample volume with 5 slices. It can be seen that on the 10th iteration there
was a minimum of 4758 violation points, however the process is terminated after
another 5 • 2 = 10 iterations because by the 20th iteration vio-pts is still above 5000.
The subsections described above combine together to form the DOPAL algorithm,
in which the dosimetry planning problem is solved. The output of the DOPAL al
gorithm is essentially the dosimetry plan, which is represented by a variable named
DOPALSDseeds.

3.3

ID D O A lgorith m D escrip tion

This section gives an in-depth description of the IDDO algorithm. The details on the
formulation and solving of the IDDO problem are given in section 3.3.1. Section 3.3.2
provides the details of the optimization routine employed by the IDDO algorithm.
Figure 3.10 explains the details of this algorithm.

3.3.1

IDDO Problem Formulation

Similar to DOPAL, IDDO also requires the contour information of the tumor volume
to start with. Unlike DOPAL however, (in which voLcontour was made up of all slices
up to and including the particular slice of interest), IDDO deals with the entire tumor
volume all at once to achieve a volume-wise optimal seed compensation. Therefore,
the volume contour information provided to IDDO does not have to be segmented.
Even so, the same segmented volume from DOPAL are currently used for simplicity
purposes. As inputs, the IDDO algorithm requires a set of seeds from pre-planning
(preplanseeds) as well as a set of currently deposited seeds (cur.depseeds). Using
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Figure 3.10: Flowchart for IDDO
these two sets of seeds, IDDO can then calculate the desired dose (desd.dose) due
to preplan.seeds, also the actual dose (cur-dose) due to cur.dep.seeds. These values
are required to achieve the goal of the IDDO algorithm, which is to compensate for
any cold spots (underdosed target volumes) or hot spots (overdosed target volumes)
caused by seed misplacements.
Additional seeds can be added for any cold spots; however seeds cannot be removed
to compensate for any existing hot spots. Thus the optimal plan devised by IDDO
is one where the overall sum of overdose and underdose is kept to a minimum. It is
worthwhile to note here that the IDDO algorithm is designed not only for use with
the DOPAL algorithm, but also as a stand-alone algorithm by itself, provided that
it is given vol.contour, preplan.seeds and cur.dep.seeds. Either way, there are two
scenarios that need to be taken into consideration.
The first scenario is that the dosimetry from preplan.seeds provides perfect cov
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erage to the entire tumor site, thus the only concern for IDDO is to compensate for
seeds that have deviated from the original dosimetry plan. To do so, the user has
to specify an accepted percentage tolerance value (toLval), on both the target vol
ume contour, as well as the forbidden volume contour if applicable, to formulate new
values for Ub and Lb as given in Eq. (3.14):
Uf, = (desd-dose due to preplan seeds) + toLval
(3.14)
Lb = (desd-dose due to preplanseeds) —toLval
For instance, if toLval is specified as 5%, and the pre-planned dose is 100%, then the
new Ub would be 105%, whereas the new

would be 95%. Also, since preplanseeds

in this scenario provides a perfect coverage, the desired amount of dose at each contour
point desd-dose is thereby equal to the dose due to preplanseeds.
The second scenario deals with an imperfect dosimetry due to preplanseeds. In
which case, the result of IDDO must be an improvement from the dosimetry of pre
planseeds. To put the second scenario in another way, the pre-planned seeds provided
to IDDO are incapable of delivering the desired dose to all regions of the target vol
ume, thus it is insufficient for IDDO to only compensate for seed deviations from
preplanseeds, since this is still not enough to produce a complete coverage to the
entire target volume. IDDO in this case should know the actual desired Ub and Lb
values imposed on the target volume, so that in addition to compensating for any
seed deviations from preplanseeds, IDDO may also take the liberty to add extra seeds
in an attempt to compensate for the cold spots from the original dosimetry. In this
scenario, there are no values specified for toLval, rather the desired Ub and Lb values
must be specified manually, for instance at 120% and 100%. In addition, the deter
mination of desd-dose at each contour point can no longer be based on preplanseeds,
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which means that the desired dose for both the target and forbidden contours are no
longer equal to the dose from preplan.seeds, instead they must be specified manually
like it has been done in DOPAL using Eq. (3.13).
In any case, based on desd.dose and cur.dose, the required dose (req.dose) at each
of the contour points throughout the volume can be calculated, req.dose is really
the amount of dose that must be delivered to each contour point to produce a full
coverage to the entire target volume. The values in req.dose are going to be different
to each other, in contrast to desd.goal for the DOPAL algorithm, which were all
identical to each other. This is because req.dose is the difference between desd.dose
and cur-dose, as shown in Eq. (3.15), where values for cur.dose for instance, are
likely to be 46.35% as a result of cur.dep.seeds, as compared to say exactly 100% for
desd.goal from DOPAL.

req.dose = desd.dose —cur.dose

(3.15)

The next step in the algorithm is to check for the amount of violation cur
rently present, based on cur.dose and the new

and L^. Similar to how it was

done in DOPAL, this volume wise violation amount is stored and referred to as
min.vioamt.IDDO. As new seed locations (new.seeds.IDDO) are generated by the op
timization routine, its corresponding volume wise violation amount cur.vioamt.IDDO
is calculated and compared to the currently stored min.vioamt.IDDO. The value of
min.vioamt.IDDO will get overwritten by cur.vioamt.IDDO if and only if IDDO
produces a plan with better dose coverage and less violations.
It is worth noting here that the user is also given the option to choose whether the
amount of violation should take into account the total number of seeds to be used. If
the user chooses not to include the weight of the seeds, this means that the calculated
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cur.vioamtJDDO is equal to the absolute violation only, which is the summation of
the amount of overdose and underdose throughout the volume; otherwise 70% of
the violation will come from the amount of overdose or underdose throughout the
volume, whilst the remaining 30% comes from the total number of seeds that are
implanted. These percentage values at this stage are completely experimental and
do not reflect the actual effort in implanting an extra seed in to the tumor site. For
now, the absolute violation option has been employed, which means that the number
of implanted seeds plays no role in the calculation of the overal amount of violation.

TopN W = min(Px) D max(Py) fl max(Pz).
TopN E = max(Px ) fl max(Py) fl max(Pz)
TopSW = min(Px) D min(Py) fl max(Pz)
TopSE = maxiPx) fl min(Pv) fl max(Pz)
(3.16)
B otN W = min(Px) fl max(Py) D min(Pz)
B otN E = max(Px) D max(Py) fl min(Pz)
B otSW = min(Px) fl min(Py) fl min(Pz)
B otSE = max(Px) fl min(Py) n min(Pz)
Next, the x and y bounds for the potential locations of the seeds must be specified.
The placement of seeds in IDDO is different to the placement of seeds in DOPAL,
where seeds were placed only on the current slice of interest. In IDDO, the algorithm
has been designed to facilitate seed placement at any location throughout the volume.
This freedom in placing a seed anywhere in the volume is only made available with
the brachytherapy set-up at CSTAR (a more detailed description can be found in
section 4.1.1.2), which allows seed deposition at any arbitrary location due to the
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Figure 3.11: Bounding volume for seed locations for the IDDO algorithm
absence of a template grid. To this end, the IDDO algorithm has to specify bounds
for the seeds in all three ( X Y , X Z and YZ ) planes. As such, a rectangular volume
is created based on the minimum and maximum values of the 3D coordinates of the
volume contour. The eight corners defining the bounding volume are given in Eq.
(3.16).
This bounding volume encloses the entire target volume, as well as some space
exterior to it (Fig. 3.11). As a result, a verification process has to be run on the
actual location of the seeds after every optimization call to make sure that the seed
has actually fallen inside the target volume and not outside of it. In Eq. (3.16),
TopN W represents the north-west corner of the top of the volume, while BotSE
represents the south-east corner at the bottom of the volume. Px, Py and Pz are the
collection of x, y and z coordinates of the contours from all slices. The volume contour
shown in Fig. 3.11 is the actual contour of a sample lung tumor made specifically for
this project, and the dotted lines represent the bounding volume.
For a more regular 3D volume (such as a sphere), a more elegant and efficient
algorithm was devised to define the boundaries of the potential locations of the seeds.
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This algorithm makes use of the fact that if the spherical volume was placed on the
xyz coordinate system, where the center of the volume coincided with the center of
the coordinate system, then the top half of the volume is more or less a mirror-image
of the bottom half of the volume. Based on this fact, several rectangular volumes are
created. The combination of all these rectangular volumes approximate the overall
spherical volume where each rectangular volume defines one volumetric space for the
placement of the seeds.
This algorithm works better with an even mumber of slices, though it is still
applicable to an odd number of slices. For the former, if the center of the volume is
treated as 0, then the first rectangular volume is created from the slices immediately
above (+1 slice) and below (—1 slice) this center. The cross-sectional view of the
l si rectangular volume is shown in Fig. 3.12(a). The assumption here is that for a
relatively spherical body, these two slices will have similar, if not identical coordinates
defining their respective contours. As such, these two slices can be considered as
‘corresponding slices’, which implies that using the planar bounds created from these
two slices as the top and bottom surfaces, a rectangular volume can be formed by
joining up the eight corners of the two planar bounds. Moreover, this volume will
more or less be in the shape of a rectangular volume. The volume is still defined by
the equations in Eq. (3.16); however Px , Py and Pz are now the contours of slices
+1 and —1, instead of being the contours of the entire volume. The 2nd rectangular
volume is constructed using the same set of equations but Px, Py and Pz take up the
coordinate points of slices + 2 and —2, because the slices of interest here are +2 and
—2. Similarly, the 3rd volume is constructed using slices +3 and —3, and so on and
so forth.
As more rectangular volumes are constructed this way, the corresponding slices
become farther apart from the center of the volume and from each other. So the
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(a) Cross-sectional view of
the bounds for the 1st vol
ume

(b) Cross-sectional view of
the bounds for the 4th vol
ume

(c) Cross-sectional view of
the bounds for the 5th vol
ume

(d) Planar bounds as top
and bottom surfaces for the
1st volume

(e) Planar bounds as top
and bottom surfaces for the
4th volume

(f) Planar bounds as top
and bottom surfaces for the
5th volume

Figure 3.12: Cross-sectional and planar views of IDDO bounds
volumes have progressively smaller top and bottom surfaces (planar bounds) due to
less 2D areas covered by Px and Py of the corresponding slices but greater length in
the z direction due to the slices being farther apart from each other. Figure 3.12(b)
shows the cross-sectional view of the 4 ^ volume, and Fig. 3.12(c) shows the crosssectional view of the 5 ^ volume. Comparing Fig. 3.12(b) and (c) to Fig. 3.12(a),
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it is clear that the lengths in the z direction for volumes 4 and 5 are much bigger
than that of volume 1; whereas the top and bottom surfaces of volumes 4 and 5 (Fig.
3.12(e), (f)) are becoming smaller compared to the top and bottom surfaces of the
l si volume (Fig. 3.12(d)).
The collection of rectangular volumes from all slices combine together to form
the approximate spherical volume. Each time ‘fmincon’ is invoked by the proposed
algorithm, a different volume is selected for seed placement. The aim is to go through
all the rectangular volumes the same number of times, thereby exploring all available
space in the x, y and 2 directions. This ensures that the seeds will be placed uniformly
and efficiently.
In the case of a spherical volume with a hollow tube, which is a possible repre
sentation of the urethra, the above algorithm is modified slightly to accommodate
this change. In contrast to a solid sphere where one rectangular volume is created
from two corresponding slices, now four rectangular volumes will be created instead.
The planar bounds for the top and bottom surfaces are still defined by Eq. (3.8),
so that there are now 4 regions. The rectangular volumes are still created the same
way as before, by joining up the same regions from corresponding slices, e.g., joining
region 2 on slices + 1 and —1 will create a rectangular volume that covers part of the
target volume but not the forbidden volume. In this way, 4 rectangular volumes will
be created from each pair of corresponding slices. For such a shape, the optimization
routine has to cycle through four times as many volumes on each call of ‘fmincon’
to uniformly place the seeds throughout the spherical volume. In this manner, the
placement of seeds in the forbidden (hollow) region of the volume will be avoided
with the best effort.
Having specified the bounds for potential locations of a seed in all (x, y and
z) directions, the last requirement prior to invoking the optimization routine is to
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provide the location of an arbitrary temporary seed (temp.seed). Similar to how it
has been done in DOPAL, temp.seed for IDDO is also calculated using the COM
formula given in Eq. (3.2a) and Eq. (3.2b). The goal of the optimization routine is
to move temp.seed to a location that will provide an optimal radiation coverage to
the whole target, confined in the space set by the equations given in Eq. (3.16). The
actual location of the seeds (new.seedsJDDO) produced by the optimization routine
are checked and verified to make sure that they are all within the tumor volume, while
the overdose and underdose violation amount due to new.seedsJDDO are calculated
again.
This process is repeated for a maximum of 10 iterations, unless convergence has
been reached before then. This number has been chosen experimentally and can be
varied as desired. During these iterations, the current minimum violation amount
cur.vioamt.IDDO is checked every time new.seedsJDDO is produced by IDDO. If
IDDO’s current violation amount due to newseedsJDDO is lower than the currently
stored min.vioamt.IDDO, then final.seeds.IDDO, which is the eventual output of the
IDDO algorithm, gets replaced by new.seedsJDDO and min.vioamt.IDDO gets re
placed by cur.vioamt.IDDO and the optimization process can continue on for another
10 iterations. The only condition under which IDDO is terminated immediately is
when cur.vioamt.IDDO due to new.seedsJDDO happens to be 0, implying that all
contour points in the entire volume are within the accepted upper and lower limits of
the prescribed dose. At this time, final-seeds.IDDO is replaced by new.seedsJDDO
and gets produced by IDDO as the final solution.
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3.3.2

ID D O ’s

<
‘f m i n c o n ' >

The IDDO algorithm also uses the ‘fmincon’ optimization routine from MATLAB’s
optimization toolbox. In contrast to the complex objective function that governed
the optimization of the pre-planning algorithm, this particular objective function
(IDDO-Obj-Fn) is given below simply as:
n
Minimize {^\req-dose(i) —D(z)]2}

(3-17)

¿=0

where req-dose(i) and D(i) correspond to the required dose and the actual dose at the
ith point on the contour volume, respectively. D(i) here is the summation of dose from
all seeds that are currently inside the tumor volume, which consist of cur.dep.seeds
and newseedsJDDO. Thus, the aim of the objective function in Eq. (3.17) is to
minimize the squared sum of the difference between the actual dose delivered and the
desired dose at each point on the contour volume.
The optimization constraints for the IDDO algorithm, IDDO-Opt-Cons, are also
similar to the pre-planning optimization constraint in Eq. (3.13). In a sense that it
also specifies a certain spacing between adjacent seeds (given below in Eq. (3.18)).
The only difference here is that the spacing is defined in three-dimensional space
whereas for pre-planning, the spacing was only applicable in the XT-plane. So that
for every ith seed, S{, that belongs to the matrix of seeds Sxy, the IDDO-Opt.Cons
is:

\\Si+i- 5t-|| > k,for Si eS~xy
where || • || is the Euclidean norm in 3D space.

(3.18)
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C h apter 4
E x p erim en ts and R esu lts
This chapter presents information on how the experiments were conducted on a vari
ety of shapes in the simulation environment, as well as in the ex vivo environment on
sample lung tumors and prostate phantoms. The equipment involved in the exper
iments for ex vivo lung tumors and prostate phantoms is described in section 4.1.1.
Section 4.1.2 and 4.1.3 give a description of the evaluation procedure for DOPAL
and IDDO respectively, with particuar focus on how to use an existing dosimetry
planning software to verify the accuracy of these proposed algorithms. Lastly, the
experimental results are presented in section 4.2 and discussed in section 4.3.

4.1

E xp erim en tal E valuation P roced u re

In this section, first, the equipment used to evaluate the proposed algorithms is pre
sented, followed by a detailed description on how an existing dosimetry planning
software will be used to verify the accuracy of both DOPAL and IDDO.

4.1.1

Equipment Set-up

4.1.1.1

Additional Software

Seed configurations for both DOPAL and IDDO are obtained in the MATLAB envi
ronment, since both algorithms have been programmed in MATLAB. However, MATLAB alone is not sufficient for evaluating the accuracy of these algorithms. As such,
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a dosimetry planning software provided by Dr. Fenster at Robarts, is used to com
pare and verify the accuracy of the dosimetry planning results produced by DOPAL.
This software will be referred to as RDP, short for “Robarts Dosimetry Planning”
software, for ease of reference. A commercial version of this software for prostate
brachytherapy is called Sonographic Planning for Oncology Treatment (SPOT) and
was described in section 2.1.1. The RDP software used for this project was modified
by the Robarts group for the lung brachytherapy project in [50].
4.1.1.2

Additional Hardware

As described in Chapter 3, both DOPAL and IDDO require a set of contour images
of the target volume before they can be executed. Therefore accurately obtaining
US images of the tumor volume is crucial for the evaluation of the algorithms. To
this end, an ultrasound machine (Philips iU22) shown in Fig. 4.1 was used to obtain
the US images for ex vivo lung tumors. The tumors were constructed based on
the approach in [55]; the tumors have diameters 5mm, 10mm and 20mm. Tumors
in operable lung cancer patients are generally less than 3cm across [56]. For our
experiments, the tumors were made from agax (Sigma Gelrite Gellan Gum), water
and barium, and were heated before they were injected into cold, collapsed porcine
lungs. The lungs with injected tumors were refrigerated overnight for the tumors to
solidify. The C-Arm was used to verify the location of the tumors prior to acquiring
the US images using the Philips iU22 US machine. A sample x-ray image obtained
from the C-Arm is shown in Fig. 4.2. Tumor 1 in Fig. 4.2(a) is smaller in comparison
to the other tumors in Fig. 4.2(b), where the tumors above the lobe (tumors 3 and
4) are considerably larger.
For prostate brachytherapy on the other hand, to obtain US images for the lifesized prostate phantom shown in Fig. 4.4, the TRUS probe in Fig. 4.3 is used, which
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Figure 4.1: Philips iU22 ultrasound machine

(a) X-ray image showing locations of
tumors 1 and 2

(b) X-ray image showing locations of
tumors 2, 3 and 4

Figure 4.2: X-ray images of samples tumors in pig lung
is a part of the prostate brachytherapy set-up from CSTAR [57].
The prostate phantom in Fig. 4.4 was not built for this project; however it is still
applicable to the research conducted in this project since the size of the phantom

_
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Figure 4.3: Prostate brachytherapy set-up at OSTAR

Figure 4.4: Life-sized prostate phantom
matches that of a prostate from real life. Nonetheless, it is necessary to evaluate
both DOPAL and IDDO algorithms on more than one test subject. To achieve this
goal, two sets of US images were acquired using the same phantom. In the first set
of images, there was slightly more noise present, which made it difficult to identify
the whole prostate; while the second set of images contained little noise so that the
entire prostate was easily identified. The ends of the figure in the first set of images
(where there were more noise) were deleted from the image set, thereby resulting in
a prostate that was slightly smaller than the prostate from the second set of images.
In terms of seed placement, the AESOP brachytherapy set-up shown in Fig. 4.5
was used. This equipment is different from the current clinical set-up, in the sense
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that there is no seed template (that was shown in Fig. 1.2) required to deposit the
seeds at their desired locations. Furthermore, the AESOP set-up provides improved
precision in seed placement such that the locations of the needles no longer need to
be specified in terms of the hole location on the seed template. Instead the location
of the seeds can be specified in terms of its desired xyz Cartesian coordinates. This is
in the best interest of the IDDO algorithm, which has been implemented to deposit
seeds at any location within the volume to achieve an optimal radiation coverage of
the tumor. In fact, the algorithms described in Chapter 3 were designed to be used
with a robotics-assisted brachytherapy set-up, similar to the AESOP set-up in Fig.
4.5, for use in the prostate, the lung and possibly other organs where seed insertion
could be done from various angles due to the absense of a seed template.
However, there is also a disadvantage associated with it from the algorithm imple
mentation point of view. If a seed template is in place, then there would be a limited
number of potential seed locations, as is the case with Lee’s MIP optimization. In the
absence of a seed template, associated with the AESOP set-up is an infinite number
of potential seed locations, making the optimization problem more difficult to solve
because more calculations and more logical eliminations are required to determine
the seed locations of an optimal plan.
With these additional hardware and software, the DOPAL and IDDO algorithms
can be properly evaluated. The evaluation procedure for these algorithms are de
scribed below.

4.1.2

Evaluation Procedure for DOPAL

The evaluation of the performance of the algorithms starts with simple 2D shapes
such as a circle, or a planar donut (a simplified representation of a prostate with the
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Figure 4.5: AESOP brachytherapy set-up at OSTAR

Figure 4.6: 2D view of the prostate with urethra
urethra), before moving on to a slightly more complicated scenario such as a realistic
planar view of the prostate with the urethra, as shown in Fig. 4.6.
The next step of the evaluation process involves performing dosimetry planning
on simple 3D shapes, such as a solid cylinder, a cylinder with a hollow tube or, a
sphere with a hollow tube. These figures are shown in Fig. 4.7.
The DOPAL algorithm is invoked to produce a dosimetry plan on the shapes
illustrated in Figs. 4.6 and 4.7, their corresponding results are presented in section
4.2.1 and section 4.2.2. The target regions have all been assigned a Ub value of 110%
of the desired dose, and a Lb value of 90% of the desired dose. The Ub and Lb values
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(a) Solid Cylinder

(b) Cylinder with Hollow tube (c) Sphere with Hollow tube
Figure 4.7: Simple 3D shapes

assigned to the forbidden regions in Fig. 4.7(b) and Fig. 4.7(c) are 110% and 80% of
the desired dose, respectively. These values were chosen relatively close to the desired
dose at 100% to reflect the accuracy of the DOPAL algorithm. Depending on the
and Lf, values chosen, the resulting coverage would also be different.
To evaluate the performance of the algorithms for ex vivo tumors against existing
dosimetry planning software such as RDP, dosimetry plans created by DOPAL are
imported into RDP and compared against RDP’s own optimized dosimetry plans.
As described in section 3.2, DOPAL requires only the 3D contour of the target vol
ume, which may be acquired through any imaging modality. However, to prove that
DOPAL is working correctly, the same target volume information also has to be pro
vided to RDP for verification purposes. Due to the fact that RDP works exclusively
with US images, these experiments were therefore limited to the US imaging modality
only.
After obtaining the ultrasound images of the tumors as explained in section 4.1 .1 .2,
the images are imported into RDP for contouring. Contouring in RDP has to be
done manually by clicking and selecting points on every slice of the target volume.
The minimum interval for contouring in RDP is 1mm along the 2-axis, however the
minimum interval at which the contour can be viewed is 2.5mm, as shown in the
bottom of Fig. 4.8. As a result, needles and seeds can only be added to consecutive
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Figure 4.8: 3D view of a sample tumor in RDP
contours at multiples of 2.5mm, meaning that the minimum spacing between seeds
on adjacent slices is 2.5mm if added manually. Needles and seeds can also be added
to slices that are 5.0, 7.5 or 10mm apart, and so on up to the last contour in the
volume. For instance, if the first contour slice is placed at z = 0mm, then seeds can
only be added on slices with a 2-coordinate of 2.5, 5.0, or n x 2.5, where n is the
nth consecutive slice from the first slice. This implies that the 2-coordinate of a seed
(Sz) must be at a distance of multiples of 2.5mm from where the first slice is, which
effectively limits the location of the seeds produced during pre-planning and seed
compensation. Even if DOPAL can be designed to cope with this, the same cannot
be done for IDDO since seed compensation should produce seeds anywhere inside the
tumor volume as long as a compensated coverage can be obtained. This is to say that
seeds produced by IDDO cannot be placed in RDP for verification purposes.
Nonetheless, the target volume is in fact defined by a discrete number of slices, so
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to get a 3D surface rendering of the target volume, the values in between the slices
are interpolated using RDP’s own built-in interpolation scheme. The 3D surface
rendering from RDP is a useful feature in displaying the volumetric isodose coverage,
a 3D surface rendering of a sample target volume is shown in Fig. 4.8.
Next, the set of points describing the volume is recorded and stored in RDP, how
ever RDP offers no direct exportation to MATLAB so the only way to use this infor
mation in MATLAB is to first store it in another program, say for example Microsoft
Excel™. Once the 3D contour information has been pasted into Excel, which contains
the x , y and z coordinates of the volume contour in a slice-by-slice arrangement, it
is then imported into MATLAB for use in the DOPAL and IDDO algorithms. The
results obtained from these algorithms can be compared against the results obtained
from RDP.
RDP also contains an optimization feature that can generate dosimetry plans
automatically. Spacing between neighboring seeds on the same slice can be selected
as either 5m m or 10mm; spacing between neighboring seeds on adjacent slices can also
be selected as either 5mm or 10mm. Therefore there are a total of four optimization
schemes from RDP, so in total 4 dosimetry plans are generated by RDP for the ex
vivo lung tumors and the prostate phantoms.
To compare the above dosimetry plans from RDP against the dosimetry plan
from DOPAL, we use several parameters obtained from the Dose Volume Histogram
(DVH), as done in [47, 50, 58, 59, 60]. A sample DVH graph is shown in Fig. 4.9,
where the percentage dose is the horizontal axis while the percentage volume is the
vertical axis. In Fig. 4.9, approximately 83.8% of the volume is receiving 100%
of the dose as indicated. To evaluate the dosimetry plan for a lung tumor, we use
the same DVH parameters as the ones that are used in [50], they are D90 (dose to
90% of the volume), V90 (volume receiving at least 90% of the dose), V I00 (volume
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Figure 4.9: Sample Dose Volume Histogram from RDP
receiving at least 100% of the dose) and V 200 (volume receiving at least 200% of the
dose). The V90 and V I00 parameters have been shown to be uninfluenced by seed
misplacements, which implies that values close to 100% for these two parameters will
ensure a good plan has been achieved. For prostate brachytherapy, D90, D100, V100,
V I20 and V I50 are used in [47, 58, 59, 60]. These parameters will also be used in
this thesis. Reference [6] also provides recommended values for V150 and D90 for an
optimal plan in prostate brachytherapy.
In order to obtain DVH parameters in the same environment so that they are
consistent between both RDP and DOPAL, it was decided that the DVH function
from RDP will be used instead of writing another program in MATLAB to do the
same thing. To obtain DVH parameters for the dosimetry plan from DOPAL, the
seeds from the DOPAL plan must be plotted in RDP, where a xyz translation was
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performed to translate the seeds from MATLAB units to RDP units. In RDP, and
like in any other dosimetry planning software, the position of the needles and seeds
can be viewed after they have been added manually. In contrast, now that the desired
locations of the seeds are known, needles and seeds can be added accordingly. By
activating all the seeds that are deposited at their desired locations, an overall sliceby-slice isodose coverage can be obtained similar to the one shown in Fig. 1.4. An
isodose coverage shows regions within a target volume receiving the same amount of
dose. Then the pre-planning DVH parameters from both RDP and DOPAL can be
obtained from their corresponding DVH graphs like the one shown in Fig. 4.9.
The pre-planning results obtained from RDP and DOPAL are presented in section
4.2.2. The discussion of these results are given in section 4.3.2 for the lung tumors
and section 4.3.4 for the prostate phantoms.

4.1.3

Evaluation Procedure for IDDO

To verify the functionality of the IDDO component, a portion of the seeds obtained
from DOPAL are manipulated such that the new coverage is no longer the same as
the coverage of the original plan from DOPAL. These manipulated seeds are used
as an input (cur-depseeds) to the IDDO algorithm, and IDDO is asked to generate
new locations for the remaining seeds (newseedsJDDO) in order to compensate for
the manipulations that took place. The final coverage as a result of the combination
of cur-depseeds and newseedsJDDO should satisfy the imposed upper and lower
limits of the accepted dose. These limits were described in section 3.3.1, the values of
which can be either the summation of pre-plan’s intended dose and the user-specified
toLval or new upper and lower limits specified by the user.
Unfortunately, the result of IDDO - newseedsJDDO, cannot be plotted in RDP
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for comparison like it was done for DOPAL. This is because the result produced by
IDDO contains seeds throughout the entire tumor volume, not necessarily fixed to the
available slices. As mentioned previously, since the seeds produced by IDDO cannot
be plotted in RDP to verify their accuracy, 3D radiation coverage graphs are then used
to compare the seed compensation results before and after running IDDO. A separate
program was written solely for this purposes, which is called isodoseSD. It displays
the isodose coverage, in both planar (2D) and volumetric (3D) views. The coverages
shown by isodoseSD will be used to evaluate the accuracy of the IDDO algorithm.
The seed compensation figures are presented in section 4.2.4 and the discussion on ex
vivo lung tumors is given in section 4.3.3 and in section 4.3.5 for prostate phantoms.

4.2
4.2.1

R esu lts
R esult for 2D Shapes

Figure 4.10 shows the simulation results of the simple 2D shapes. Figure 4.10(a), (c)
and (e) show the configuration of the seeds according to the dosimetry plan produced
by DOPAL, their corresponding radiation coverages at 100% of the prescribed dose
are shown in Fig. 4.10(b), (d) and (f). It can be seen from Fig. 4.10(a) and (c) that
for circular shapes, the seed arrangements are very uniform, even in the presence of an
enclosed circle as in Fig. 4.10(c). As a result, Fig. 4.10(b) and (d) show very uniform
and complete radiation coverages at 100% of the prescribed dose. The robustness of
the algorithm is illustrated in Fig. 4.10(e) and (f), where the seed arrangement and
the 100% radiation coverage are also uniform and complete, even though this time it
is for an irregular, complex shape such as the prostate with the urethra.
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(a) Seed placement in Circle

(b) Radiation coverage of Circle

(c) Seed placement in Coax Circle

(d) Radiation coverage of Coax Circle

16

(e) Seed placement in Prostate

(f) Radiation coverage of Prostate

Figure 4.10: Simulation results for simple 2D shapes
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Figure 4.11: Simulation results for simple 3D shapes
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4.2.2

R esult for 3D Shapes

The simulation results for simple 3D shapes are shown in Fig. 4.11, the shapes of
interest here are the Solid Cylinder (Fig. 4.11(a)), a Cylinder with a Hollow tube
(Fig. 4.11(b)), and a Sphere with a Hollow tube (Fig. 4.11(c)). In Fig. 4.11, the
location of the seeds for each shape is shown in the first row of each column, while
the 100% radiation coverage due to the seeds viewed in X Y , X Z and Y Z planes are
shown underneath for a complete illustration. The radius of the cylinders and sphere
are different from each other, and the radius of the hollow tubes are also different.
This was done purposefully to demonstrate that the algorithm works for all shapes
and sizes.
In the first column, the radius of the cylinder (r.cyl) is given a value of 5 units.
Figure 4.11(d) shows that the coverage at 100% of the prescribed dose in the X Y
plane is complete and uniform, however the coverages in X Z and Y Z planes shown in
Fig. 4.11(g) and (j) are spherical toward the two ends of the cylinder. This occured
because of the absence of the constraint that governs the distance between adjacent
seeds (Eq. 3.13), and was in fact done on purpose to illustrate the effect and the
importance of this optimization constraint (details on this was explained in section
3.2.3). Examining the distribution of the seeds in Fig. 4.11(a), it can be seen that
the seeds bunch together in the center of the top and bottom slices. This bunching of
seeds has led to the hemi-spherically shaped coverages on the top and bottom slices
shown in Fig. 4.11(g) and Fig. 4.11(j). To prevent this from happening again, the
optimization constraint of the neighboring seeds are made available in DOPAL for
dosimetry planning for the Cylinder with a Hollow tube (Fig. 4.11(b)) and the Sphere
with a Hollow tube (Fig. 4.11(c)).
The cylinder in Fig. 4.11(b) has a r-cyl value of 9 units, while the hollow tube has
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a radius (r.tube) of 3 units. The seeds in this figure can be seen to have assumed an
uniform distribution, which resulted in uniform and complete coverages in the X Y ,
X Z and Y Z planes shown in Fig. 4.11(e), (h) and (k).
Similarly, uniform and complete coverages have been achieved in all X Y , X Z and
Y Z planes for the Sphere with a Hollow tube, where the radius of the sphere (rsp h )
is 10 MATLAB units and r.tube is 2 units. The only drawback here are the small
underdosed regions (cold spots) close to the top and bottom slices of the sphere shown
in Fig. 4.11(i) and (1). Had this been a solid sphere without a forbidden region, these
cold spots would not have been present. The top and bottom slices of the sphere have
a target radius of only 6 units, where r.tube is consistently at 2 units from one end
to the other. The value of r.tube on these slices in relation to thè“ relatively smaller
value of r.sph makes it difficult to deliver the perfect amount of dose to these slices.
Despite the observable cold spots for the coverage at 100% of the prescribed dose,
these regions are fully dosed at 90% of the prescribed dose, therefore still satisfying
the Ub and L^ conditions.

4.2.3

e x v iv o

and Phantom Pre-planning R esults

The effectiveness of the dosimetry plans from DOPAL on ex vivo tumors and prostate
phantoms are compared against all four of RDP’s optimization schemes. The most
optimal plan would consist of high values (~ 100%) for V 100 parameters, and low
values for 1/200 or 1/150 parameters. This is beacuse the amount of dose delivered
to the entire volume should be as close to 100% of the prescribed dose as possible,
while the amount of volume receiving > 100% of the prescribed should be limited in
order to prevent damage to the surrounding anatomical structures.
Tables 4.1-4.3 show the DVH values of all five plans (4 from RDP and 1 from
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Table 4.1: DVH parameters of 5mm diameter tumors
Plan
D90
V90 V100 V200
64% 56.9% 19.5%
82.5Gy
DOPAL
74% 31.9%
109.9Gy 80%
DNE
DNE DNE DNE
RDP 5.5
54.9Gy 61.9% 58.7% 33.8%
DNE DNE DNE
DNE
RDP 5.10
DNE
DNE DNE DNE
DNE DNE DNE
DNE
RDP 10.5
DNE
DNE DNE DNE
DNE
DNE DNE DNE
RDP 10.10
DNE
DNE DNE DNE

DOPAL) for lung tumors with diameters of 5mm, 1cm and 2cm. These tumor sizes
were selected because the tumors found on clinically operable patients are less than
3cm as suggested by [56]. The first row under each plan name refers to the first
experimental tumor while the second row refers to experimental tumor number two.
The convention used to distinguish the four different plans from RDP is done by the
use of two numbers, for example in RDP5-5, the l si number represents the distance
between neighboring seeds on the same slice, while the 2nd number represents the
distance between neighboring seeds on adjacent slices. The results in these tables are
obtained using the default value for the initial strength of the source at If/.
One thing worth mentioning here is that when DOPAL was used on the 1cm
tumor, the

and

values were specified as 10% higher than the

and

values

for the 5mm and 2cm tumors. This resulted in the elevated values for the D90 and
V200 parameters in Table 4.2, in comparison to the lower D90 and V200 values in
Tables 4.1 and 4.3.
Table 4.4 shows the DVH values of all five plans for the target region of the prostate
phantom, and Table 4.5 shows the DVH values of all five plans for the urethra region.
Both tables follow the same convention to the lung tumor tables, where the first row
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Table 4.2: DVH parameters of 1cm diameter tumors
V90 V100 V200
Plan
D90
169.lGy 97.2% 95.3% 51.7%
DOPAL
160.lGy 96.7% 93.7% 59%
163.9Gy 99% 94.4% 60.4%
RDP 5_5
146.lGy 92.8% 90.4% 71.3%
76.1Gy 68.3% 60.1% 32.4%
RDP 5.10
133.lGy 89.6% 88.2% 69.8%
30.lGy 27.4% 26.4% 10%
RDP 10.5
DNE DNE DNE
DNE
27% 25.7% 10.5%
30.1Gy
RDP 10_10
DNE DNE DNE
DNE

Table 4.3: DVH parameters of 2cm diameter tumors
V90 V100 V200
D90
Plan
149.9Gy 96.7% 92.1% 40.5%
DOPAL
140Gy 93.3% 88.8% 54.2%
24.6Gy 28.1% 26.6% 12.3%
RDP 5_5
185.4Gy 98.8% 98% 70.5%
24.6Gy 28.3% 27% 12.3%
RDP 5.10
133.9Gy 91.2% 87.4% 51.4%
DNE DNE DNE
DNE
RDP 10_5
106.3Gy 78.8% 71.6% 27.5%
DNE DNE DNE
DNE
RDP 10.10
84.4Gy 63.8% 55.8% 19.1%

under each plan name represents the values for the l si prostate phantom, and the
second row represents the values for the 2nd phantom. The naming of the dosimetry
plans in these table also use the same convention as before.
Lee’s results from [47] are also presented in these two tables. Due to the 0.571/
source strength used in [47], DOPAL and RDP results in Table 4.4 and 4.5 have also
used the same source strength. Reference [47] presents the DVH values for certain
parameters only, thus Not Available (N/A) are used in places in Tables 4.4 and 4.5
where values for the desired DVH parameters from [47] are unknown.
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Table 4.4: Target DVH parameters of prostate phantoms
Plan
D90
D100
V93 V100 V150
150.9Gy 87.5Gy 96.7% 93.3% 40.8%
DOPAL
153.lGy 99.7Gy 96.8% 94% 42.3%
115.8Gy 50.8Gy 85.9% 83.4% 57.4%
RDP 5.5
129.9Gy 68Gy 88.9% 86.6% 65.8%
115.4Gy 42.8Gy 85.5% 82.7% 58%
RDP 5.10
127Gy 68.5Gy 87.8% 85.2% 62%
23.7Gy 9.7Gy 28.8% 25.4% 9.9%
RDP 10.5
34.2Gy 20.9Gy 22 .6% 20.2% 9.0%
13.6Gy 5.8Gy
7.2% 4.7% 3.5%
RDP 10_10
lO.lGy
5.3Gy 6.3% 5.7% 3.7%
Lee
N/A
N/A
100%
N/A
N/A

4.2.4

e x v iv o

and Phantom IDDO R esults

As described in section 4.1.3, only MATLAB figures are used to verify the accuracy of
the IDDO component, which is due to the fact that IDDO allows seed placement in the
entire z-space of the target volume, meaning that the seeds are likely to fall in regions
between slices, which cannot be specified in RDP since the slices in RDP are fixed. In
any case, it would be sufficient to verify the accuracy of the IDDO component using
MATLAB figures alone, as long as the coverage displayed by isodoseSD of this thesis
(refer to section 4.1.3) can be shown to match the figures from RDP. Figure 4.12(a)
shows the isodose coverage on every slice of a target volume obtained from RDP,
and Fig. 4.12(b) shows the isodose coverage from isodoseSD of the same slices of the
same volume using the same seeds. There are only a few small differences at certain
points, the causes of which are explained in section 5.1. Nonetheless, the differences
are negligibly small so that the slice-by-slice views from RDP are considered to be
identical to the slice-by-slice views from MATLAB.
To show a different coverage to the one from dosimetry planning, seeds from pre
planning are deliberately misplaced or skipped, the resulting coverages due to this are
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Table 4.5: Urethra DVH parameters of prostate phantoms
D100
V90 V100 V120 V150
D90
Plan
142.lGy 117.1Gy 97.1% 86.4% 18.6% 0.3%
DOPAL
148Gy 122.8Gy 99.5% 95.7% 28.4% 3.7%
98.3Gy 60.6Gy 75.9% 71.7% 62.2% 42.8%
RDP 5_5
144.2Gy 92.3Gy 95.7% 90.1% 74.7% 55.9%
85.5Gy 49.6Gy 81.1% 77.1% 68% 44.4%
RDP 5.10
122.lGy 75.8Gy 87.2% 80.6% 64.6% 33.9%
0%
11.9Gy 20.8% 10 .6% 1.3%
20.2Gy
RDP 10.5
0.1 %
0.5%
35.9Gy 29.4Gy 5.3% 2.5%
0%
0%
0.5% 0. 1 %
11.3Gy
7.1Gy
RDP 10.10
0
%
0%
0
.
2
%
0
.
1
%
3.8Gy
5.9Gy
N/A > 50% N/A
N/A
N/A
N/A
Lee

(a) Slice by slice isodose views of a tumor vol
ume from RDP

0
-4-2

0

2

Xaxis

(b) Same isodose views as in Fig. 4.12(a) from

isodoseSD
Figure 4.12: Isodose comparison between RDP and isodose3D
shown in the l si and 2nd columns of Figs. 4.13 and 4.14. These two figures show the
coverage at 100% of the prescribed dose for the lung tumors in the XT-plane due to
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the pre-plan seeds, manipulated seeds as well as the compensated seeds from IDDO,
in columns 1, 2 and 3 of each figure respectively. Each row in these figures represents
the same slice.
Figures 4.17 and 4.18 provide a comparison between the original coverage (first
row in each figure), coverage due to seed manipulations (second row in each figure),
and the coverage after compensating for the manipulation by running IDDO (third
row in each figure), for the two prostate phantoms. The compensated results in Fig.
4.17(e) and (f) are obtained by running IDDO with the aid of a tolerance value, which
was specified as toLval= 5; on the otherhand, the coverage due to seed compensation
in Fig. 4.18(e) and (f) are obtained without toLval, which means that
values of the target volume were specified manually.

and Lj,

Y axis
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Figure 4.13: Before and after seed compensation for tumor 1 in AT-plane
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Figure 4.14: Before and after seed compensation for tumor 2 in XF-plane
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Coverage due to misplaced seeds
in X Z and Y Z planes

Coverage o f preplanned seeds
in X Z and Y Z planes
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Figure 4.15: Before and after seed compensation for tumor 1 in X Z and yZ-planes
Coverage of preplanned seeds
In XZ and YZ planes

Coverage due to misplaced seeds
in XZ and YZ planes

Coverage after seed compensation
In XZ and YZ planes
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Figure 4.16: Before and after seed compensation for tumor 2 in X Z and Y Z-planes

(a) Original coverage in
phantom No. 1

X Z -plane for

(b) Original coverage in
phantom No. 1

Y Z -plane for
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(c) Coverage in
-plane due to seed
manipulations for phantom No. 1

XZ

(e) Coverage in
-plane after seed
compensation with IDDO for phantom
No. 1
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manipulations for phantom No. 1
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Figure 4.17: IDDO results for prostate phantom No. 1
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(a) Original coverage in XZ-plane for
phantom No. 2

(b) Original coverage in FZ-plane for
phantom No. 2

(c) Coverage in XZ-plane due to seed
manipulations for phantom No. 2

(d) Coverage in Z-plane due to seed
manipulations for phantom No. 2
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(e) Coverage in XZ-plane after seed
compensation with IDDO for phantom
No. 2

(f) Coverage in FZ-plane after seed
compensation with IDDO for phantom
No. 2

Figure 4.18: IDDO results for prostate phantom No. 2
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4.3
4.3.1

D iscu ssion
Discussion on Simulation R esults for Simple Shapes

These simple 2D and 3D shapes are only graphed by DOPAL in MATLAB, nothing
was done in RDP because these shapes are only used to test the basic functionality
of the algorithm. As a result there are no DVH parameters available. Even so, it
can be easily seen in Figs. 4.10 and 4.11 that all the shapes have been properly
dosed, since all the 100% radiation coverages appear to cover the entire surface of the
planes (Fig. 4.10) or the entire volume (Fig. 4.11). However, realistic tumors will
never assume such perfect shapes, therefore these results are not sufficient to indicate
whether DOPAL is clinically applicable; it is merely indicating that the algorithm is
functional.
It is worth noting here that the spacing between the slices (dJi) plays an important
role in the overall coverage produced by DOPAL and IDDO. The selected value
for dJi was 2 MATLAB units for the images in Fig. 4.11. It has been verified
through experimentation that the algorithms work best with a d-h value of less than
4 MATLAB units, anything larger will force DOPAL and IDDO to deliver dose to
the specified contour slices only, leaving the space between these slices un-dosed. The
effect of this is illustrated in Fig. 4.19 using the same volume as in Fig. 4.11(b). The
only difference here is that d_/i has been increased to 10 units. The images in Fig.
4.19 clearly indicate that the large spacing in between the slices is not dosed properly,
even though each individual slice has received adequate coverage.
This is not unexpected since the optimization schemes in DOPAL and IDDO
have no knowledge of the large spaces in between the slices, for their only concern
is to deliver the desired dose to the points provided to them. This implies that
to completely dose one entire volume that is composed of well separated slices, the
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Figure 4.19: Coverage due to large spacing between slices
contours of the slices have to be traced out at no more than 4 MATLAB units, which
converts approximately to less than 15mm between slices. This does not affect the
experiments, since the spacing between slices in DOPAL can be specified as low as
1mm, as was mentioned in section 4.1.2.

4.3.2

D iscussion on DOPAL for Lung Tumors

In Table 4.1, the majority of RDP’s optimization schemes were not able to produce
a dosimetry plan, indicated by DNE (Dose Not Exist), while DOPAL was able to
produce satisfactory plans for both tumors. Comparing the only result from RDP

98
( RDP5.5) on the second 5mm tumor against the DOPAL result on the second tumor,
the first three parameters from RDP are all lower than the corresponding DOPAL
result. The only value that is higher than the value of DOPAL belongs to P200, but
this in fact is desirable to be kept low. Therefore it is clear that DOPAL performs
better than RDP when working with tumors with a 5mm diameter.
In Table 4.2, four dosimetry plans were created by RDP’s optimization schemes for
tumor 1, but only two plans were created for tumor 2. With regard to the l si tumor,
again the only comparable result from RDP to the plan by DOPAL is RDP5.5. Even
though both these plans have values for £>90 at more than 160Gy, this is acceptable
because if the entire volume is to receive 144Gy (£>100 = 144Gy), the dose to 90%
of the volume should be higher than 144Gy. Comparing DOPAL and R£>P5_5, the
plan from DOPAL has a higher P100 value and a lower P200 value than R D P 5_5,
implying that the DOPAL plan is actually more preferable. As is described in [50],
1/100 is less likely to be affected by seed displacements, so it is better to have a higher
value in order to achieve a better coverage. For the 2nd tumor, the DOPAL plan
produced better values than both RDP5-5 and RDP5A0 in terms of P90, P100 and
P200. A higher percentage volume receiving 90% and 100% of the prescribed dose
is always desirable as this implies a more complete coverage, while there should be
a lower percentage volume receiving 200% of the prescribed dose to limit radiation
to the OAR. DOPAL managed to achieve higher values than the plans from RDP
for both P90 and P100, while a lower value was achieved for P200. The plan from
DOPAL has a higher £>90 value than the plans from RDP, but this is still acceptable
since the overall radiation is actually ‘harming’ less tissue than R D P 5_5 or RDP5A0
as shown by the P200 values. The remaining results from RDP were not comparable
to DOPAL’s results and therefore they will not be discussed here.
Regarding the results of the first 2cm tumor that are displayed in Table 4.3, not
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only is RDP capable of producing just 2 valid results, but these results have extremely
low values for the 1/100 parameter, no more than 27%. Comparing this, as well as
the values of all other parameters to the values shown under DOPAL, even though
the V200 value from RDP5.5 is as low as 12.3%, but the inferior D90, 1/90 and
1/100 values mean that the prescribed dose is unlikely to be delivered to the tumor.
Therefore, this implies that the pre-plan from DOPAL is better even if the value for
1/200 is higher. As for the second tumor, the plan from DOPAL is very similar to the
one produced by RDP5.10. Although RDP5.5 has a considerably better 1/100 value
than D O PA L, the 1/200 value from this plan is far too high, thereby more likely to
cause damage to the OAR than the one from DOPAL. The 1/200 value of the latter
is about 25% lower. Like in the case of the 1cm tumors, RDPlO'Jb and RDP10A0
are all too poor compared to DOPAL and are omitted for discussion purposes.
Overall, the proposed pre-planning algorithm - DOPAL, has outperformed most
of RDP’s optimization schemes, for a range of different sized lung tumors. Not only
are most of the dosimetry plans from DOPAL more capable at delivering the desired
dose, but they are also less likely to harm other anatomical structures than the
corresponding plans from RDP.

4.3.3

D iscussion on IDDO for Lung Tumors

Since isodoseSD from MATLAB has been proven to provide identical coverage to the
isodose graphs from RDP (Fig. 4.12), the IDDO algorithm can be verified by visually
comparing the AT-plane coverage before and after updating the dosimetry plan with
IDDO’s output. The figures in the 2nd column of Fig. 4.13 show the slice-by-slice
radiation coverage at 100% prescription dose due to manipulated seeds on the 1cm
tumor, where the 1st figure in that column corresponds to the l si slice and the last
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figure is for the last slice. In this column of figures, slices 3 and 4 show the most
significant effect due to seed manipulations, where greater underdosed regions can
be observed closer to the boundary of the tumor. This is evident when compared
to the same images from the l si column, which are the 100% radiation coverages
from pre-planning. The seeds on these figures also appear to be clustered, but only
because the seeds on these slices are viewed all at once in the X Y -plane, when in fact
every individual slice contains far fewer seeds. The 3rd column in Fig. 4.13 shows the
slices after seed compensation with IDDO. Slices 3 and 4 in this column show that
the cold spots from the same images from the 2nd column are no longer present, due
to the newly deposited seeds as a result of IDDO. The new IDDO seeds are visible
upon closer inspection, since the seeds on each slice in the 3rd column in Fig. 4.13
are different from the seeds seen in the previous two columns. The overall coverage
shown in the last column is very similar, if not identical, to the original coverage in
the first column, which indicates that IDDO is working well for the 1cm tumor.
As for the 2cm tumor in Fig. 4.14, the most visible effects due to seed manip
ulations (column 2) are found on slices 4, 5 and 6. Similar to the 1cm tumor case
before, the 100% prescription dose coverages of slices 4, 5 and 6 in Fig. 4.14 due
to seed compensation by IDDO (column 3) show very well compensated coverages
since the cold spots that are visible in the manipulated coverage can no longer be
seen. Intuitively, for IDDO coverage to be similar to the original coverage, the seed
configuration from IDDO should also be similar to the original seed configuration.
This is evident when taking a closer look at the seeds present between the original
and IDDO configurations, even though the IDDO seeds are a little different from the
original seeds, they look very similar indeed.
Column 1 in Fig. 4.15 (1cm tumor) and Fig. 4.16 (2cm tumor) show the pre
planned 100% coverage in the X Z , and Y Z planes, while column 2 shows the coverage
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due to misplaced seeds and column 3 shows the coverage after seed compensation.
These figures indicate that the results for X Z and Y Z planes are consistent with
those for XT-plane.

4.3.4

D iscussion on DOPAL for Prostate Phantom s

With regard to prostate brachytherapy, both [59] and [6] have suggested adequate
values in obtaining a robust and optimal dosimetry plan. In [59], the suggested value
for 1/100 in the target region (i.e. the prostate and not the urethra) is > 80%, and
the suggested value for £>90 is between 140 to 160Gy. This matches the value given
in [6], in which the recommended value for £>90 is given as 160Gy. [6] also suggested
that an optimal plan for prostate brachytherapy should result in a value of 40% for
1/150, also for the target region.
Intuitively, the most optimal plan is one that has a V I00 value of 100% with
1/200 of 0%. Obviously this can only be a ‘goal’, since it is not realistic for prostate
brahchytherapy due to the presence of the urethra, bladder and rectum. The urethra
runs through the center of the prostate, and it would receive more dose than the
desired 100% prescription dose if the whole prostate itself has actually been delivered
144Gy of dose. Therefore the upper dose limit imposed on the urethra in [47] is
actually 150%, which resulted in the urethra from half of the test cases receiving
more than 120% of the prescribed dose. Although this value is higher than 100%, it
is to ensure that the prostate can still receive adequate dosage. Even so, the work
in [47] suggested that the dose to the rectum cannot exceed the upper limit of 78%.
The violation of this limit is strongly correlated with a high dose on the prostate
[47, 61]. It is necessary to mention here that the work in [47] has used an initial
source strength of 0.5717, which is slightly lower than the 1U source activity used
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for the evaluation of the ex vivo lung tumors. To be consistent with the work from
[47], the same source strength of 0.57U is used for evaluating the DOPAL results for
the prostate phantoms. For simplicity, the RDP and DOPAL results regarding the
prostate phantom in Table 4.4 and 4.5 are also obtained using a source strength of
0.57U.
To examine the robustness of the proposed algorithm on prostate phantoms, there
are two regions that must be examined, namely, the target region (the prostate) where
the full prescription dose should be delivered to the entire volume; and the forbidden
region (the urethra) where ideally no dose should be delivered to any part of the
region at all. First, from the urethra DVH values in Table 4.5, it can be seen that
the V150 value for both RDP5-5 and RDP5A0 are well above 30% for tumors
1 and 2. Although for each tumor RDP5.5 and RDP5A0 produced lower values
than the corresponding DOPAL result with regards to £>90, £>100, V90 and V'lOO,
the 1/120 result of DOPAL is significantly lower than both RDP5-5 and RDP5A0
which is desirbed to be kept low to prevent harming the surrounding OAR. Since it
is not possible to prevent the urethra from receiving a substantial amount of dose,
it is important that the maximum dose delivered to the urethra should be kept to a
minimum, which is described by the 1/120 value. It is safe to say that based on the
1/120 and 1/150 urethra values, DOPAL has performed better than both RDP5.5
and RDP5A0] the remaining two plans from RDP - RDP10-5 and RDP10A0 seem
to have outperformed DOPAL with regards to the dosimetric values of the urethra.
However, the DVH parameters for the prostate must also be analyzed to determine
the effectiveness of RDP10.5 and RDP10A0 versus DOPAL.
In addition, the average urethral dose has been given as 156% as a result of the
intra-operative 3D algorithm (I-3D) by [60], this translates to more than 224Gy of
dose for £>100 for the urethra. This is not at all desirable and is not comparable to
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DOPAL’s £>100, which has been kept below the prescribed dose. Also, [40] presents
the data from their research, which shows an average £>30 for the urethra from 6
patients as 180.72Gy. In comparison, the average dose delivered to 30% of the urethral
volume by DOPAL is 167.7Gy. Since the urethra is the subject of interest here, it is
desirable to have a low value for £>30. As such, DOPAL also performs better than
the method proposed in [40].
In Table 4.4, RDP10-5 and RDP10.10 also show very low values for all the DVH
parameters. Even though the low values for 1/150 is desirable, but it can be seen from
all the other values that there is hardly any dose delivered to the target volume by
these two plans. The maximum volume receiving the full amount of the prescribed
dose is from R D P 10.5, which is just over 25%. This is not a fa ll comparable to
DOPAL’s 1/100 at 93.3%. Therfore, RDP10-5 and RDP10A0 are not performing as
well as DOPAL is in delivering a good dose to the tumor volume. Furthermore, all
parameters under DOPAL show better values than all the other two plans from RDP
(RDP5-5 and RDP5-10). For £>100 and 1/100, which are parameters that should
have a high value, the values from DOPAL are much higher than those from RDP,
while 1/150, which should be as low as possible, the value under DOPAL is at least
17% lower than its corresponding value from RDP. It can be concluded then that for
the prostate phantom, DOPAL has performed much better than RDP.
The 1/100 and 1/150 values from [60] were given respectively as 96% and 71%.
This high VO00 result has been obtained at the expense of increasing dosage to the
entire volume. Evidence of this is the high 1/150 value, as well as the high urethral
dose at 156% as mentioned previously. In this respect, DOPAL is arguably better
than the I-3D algorithm proposed by [60], since DOPAL delivered a relatively high
dose to the prostate, while delivered relatively little dose to the urethra. Also, the
average 1/150 value for the prostate given by [40] is 70.3%, and the average 1/100
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value given is 96%. It can be seen that in terms of the F I 00 parameter alone the
algorithm from [40] performs better than DOPAL. However, considering the fact that
the average F100 value from DOPAL for the prostate is 93.7% (which is very close
to 96%), and that the average F150 value from DOPAL is 41.5%, and the fact that
DOPAL harms the urethra less than the algorithm from [40], in an overall sense the
DOPAL algorithm may be better than the proposed algorithm in [40].
Elsewhere, reference [62] reported that an average of 86.34% was achieved for
F100 of the prostate among data from five treatment centers, which is somewhat
inferior to the results produced by DOPAL. Also, F100 presented by [63] for the
prostate is 95%, while £>100 is 190Gy for the urethra. The F100 for the prostate
from this work is slightly higher than the result from DOPAL, however the urethral
£>100 result from DOPAL (« 120Gy) is significantly lower and thus better than the
one from [63].
The results for Lee et a/.’s work on prostate dosimetry planning are given in [47],
in which it is stated that 93% of the prescribed dose was delivered to the gland,
which can be intepreted as F93 = 100%, as shown in Table 4.4. Reference [47] also
stated that 50% (total of 15 patients) of the urethra received more than 120% of the
prescribed dose on average, with the range of the dose delivered to the urethra being
100% to 150%. This can be intepreted as F I 20 > 50% for the urethra, which is shown
in Table 4.5. Since these are the only values that are explicitly provided by [47], it is
not possible to perform a complete comparison between DOPAL and Lee’s work. For
the available values that are shown in Table 4.4, the results from Lee’s work appear
to have a slight advantage over DOPAL, their F93 value is less than 5% better than
the F93 value of DOPAL. On the other hand, no information is given regarding how
Lee’s algorithm performed in terms of £>90 and F100, but it can be seen that the £>90
results from DOPAL are within the suggested 140Gy to 160Gy range, while the F100
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results are well above the suggested adequate 80% mark. In terms of the prostate
alone, even though DOPAL did not perform as well as Lee’s algorithm did for P93,
they are still good dosimetry plans overall.
The urethra comparison against Lee’s work has to rely on the P I 20 results only.
In [47], more than 50% of the urethra volume received 120% of the prescribed dose,
whereas the values under DOPAL are at least 30% lower as shown in Table 4.5. The
one concern for the results in this table is that the results from Lee’s work were based
on 15 patients, while DOPAL’s results were from two prostate phantoms. It might
be a possibility that values for P120 will increase as more data is collected; however,
the consistency shown by the values from the prostate DVH parameters, as well as
the P120 and P150 values for the urethra is a sign that similar results to those shown
in Table 4.5 would be produced even when DOPAL is tested on a number of test
subjects.
It was also mentioned in [6] that an optimal use of the brachytherapy sources
should result in a value of 40% for P I 50 and 160Gy for D90, for the prostate. The
DOPAL results shown in Table 4.4 show that the D90 values for the two phantoms
are at 150.9Gy and 153. iGy, while the P150 values are at 40.8% and 42.3%. These
DOPAL values are very close to the values suggested in [6].
Overall, it can be concluded that DOPAL is comparable to Lee’s MIP based
dosimetry planning algorithm, if not better. The urethra is clearly receiving much
less dose with the dosimetry plan from DOPAL, even though 93% of the prescribed
dose isn’t delivered to as much of the target volume as Lee’s algorithm did.
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4.3.5

Discussion on IDDO for Prostate Phantom s

The IDDO results for the l si prostate phantom is shown in Fig. 4.17, which shows
the pre-planned 100% prescription coverage in the first row, 100% coverage due to
seed manipulations in the second row, and 100% coverage after seed compensation
with IDDO in the third row. As mentioned in section 4.2.4, the IDDO compensation
results in this figure (4.18(e), (f)) are obtained by using a toLval= ±5%, which means
that the new upper limit is now 5% more than the upper limit of the pre-planning
seeds, while the new lower limit is 5% lower than the lower limit of the pre-planning
seeds. As shown in Fig. 4.18(c) and Fig. 4.18(d), only seeds in the bottom half
of the prostate have been kept in their original positions. Upon closer inspection,
the seeds (which are hexagons in the figures) after running IDDO compensation are
different from those from pre-planning, even though the compensated coverages are
almost identical to the original coverage, even at places where a slight overdose is
visible. This further confirms that IDDO is working well, since a toLval= 5% has
been specified prior to running the algorithm, the desired outcome of which is a
compensated coverage of no more and no less than 5% of the original coverage.
For the 2nd phantom (Fig. 4.18), the seeds have been manipulated differently from
those in the 1st phantom, where the seeds have been kept on various slices throughout
the volume and not just on the bottom half. Furthermore,

and

values on the

target and forbidden regions have been specified manually in IDDO to obtain the
compensated coverages shown in Fig. 4.18(e) and (f), meaning that a toLval was
not in place. These has been done purposefully to show that the IDDO algorithm is
working for another scenario than the in the l si phantom. Although the compensated
coverages at 100% prescribed dose in Fig. 4.18 still closely resemble the original 100%
coverages, the overdosed regions on the top and bottom slices seen in Fig. 4.18(a)
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and (b) are no longer visible in Fig. 4.18(e) and (f). This can be easily explained
since a toLval was not used for this phantom, such that the seed compensation of
IDDO no longer focuses on delivering the same dose to the entire volume as the dose
from pre-plan, rather its concern now is to deliver the dose according to the new
Ub and Lf, specified by the user. Evidently, IDDO is working fine with or without
toLvai, however one can argue that it might be better to include toLval in IDDO.
Simply because in Fig. 4.17(a) and (a) the pre-planning seeds already provided a
good coverage.
In Fig. 4.18(e), the bottom slice is covered but not the space below it. This space
refers to the completeness of the prostate volume, and even though the space below
the bottom slice in Fig. 4.18(a) dose not seem to be properly covered either, at least
the two ends of the coverage are more prostate-like than those displayed in Fig. 4.18(e)
and (f). Nonetheless, the IDDO algorithm itself is proven to be fully functional and
produces the desired coverage to the tumor volume given to it. Supplying the IDDO
algorithm with a more complete description of the tumor volume would most likely
resolve the issue mentioned above regarding the un-dosed space below the bottom
slice.
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C h apter 5
C on clu sion and Future W ork
In this chapter, the sources of error that affected the accuracy of the results of this
research are first discussed. Then in section 5.2, the various areas that require further
work are discussed. Concluding remarks are given in section 5.3.

5.1

Sources o f Error

One source of error in this work comes from the slight discrepancies observed when
comparing Fig. 4.12(a) and (b). These are due to differences in the dose calculation
formulas employed by RDP and DOPAL. In the implementation of DOPAL, an inverse
squared method has been used to calculate the dose delivered to various points. In
particular, the dose calculation in DOPAL is based on the point source approximation
suggested by [5], which has also been used by Lee et al. [18] in their research. It is not
clear what is the exact formula used by RDP as it is a commercial and proprietary
package. This uncertainty is the likely cause of the offset observed in Fig. 4.12.
Reference [5] discusses the possible cause of this offset, which is likely due to the
values of the parameters involved in Eq. (2.5). It was noted in [5] that although it
is sufficient to approximate the dose using the point source formula, it might lead to
errors in the range of 3% to 9%.
Another source of error is with regard to the values presented in Tables 4.4 and
4.5 for the prostate and urethra pre-planning results, because the DVH values of the
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DOPAL plans from these tables have been obtained using different methods from
Lee’s plans. RDP was used to obtain the DVH values for the DOPAL plans, which
are then compared against Lee’s DVH values, even though there is no indication
as to how the DVH values in Lee’s work in [47] have been obtained. On the other
hand, it is justified to use RDP to obtain the DVH values for the plans generated by
both RDP and DOPAL in Tables 4.1 to 4.5, because the DVH values from DOPAL
are compared against those from RDP. Other than the fact that obtaining the DVH
values from a commercial software such as RDP provided a certain degree of validity,
it would have been better to have known the seed locations from [47] instead of the
DVH values, so that the seeds from both DOPAL and [47] can be plotted in RDP and
their corresponding DVH values can be obtained using the same program to minimize
any discrepancies.
This led to another error for the results in these tables, which is the lack of
knowledge of the prostate volume used by Lee in [47]. The results from [47] have been
obtained from a wide range of test subjects, the prostate volume in these studies are
likely to be of various shapes and sizes. As was shown by the DOPAL results for the
two prostate phantoms in this thesis, the DVH parameters for each prostate phantom
are different. So, without knowing the exact volume and shape of the test subjects
used by [47], the results displayed in Tables 4.4 and 4.5 may not provide an objective
comparison.

5.2

Future W ork

One area of improvment that can be done in the future is to test the DOPAL and
IDDO algorithms in the ex vivo environment for the lung, kidney and other organs in
the presence of forbidden regions that have a more complex shape than the urethra.
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The algorithms should work very well regardlessly of the shapes of the forbidden
regions, but tests are still planned to get a qualitative and quantitative feedback.
As was mentioned in section 4.3.4, the results in [47] from Lee’s dosimetry planning
algorithm has been tested on prostate data from 15 patients. In contrast, the DOPAL
algorithm proposed in this thesis has been verified on two sets of prostate data only.
Despite the reasonable results shown in Table 4.4 and Table 4.5, not enough results
were available to make a statistical comparison with Lee’s approach. Also, it was not
possible to draw conclusions about robustness of the algorithm by comparing only
two sets of DVH values (V93 for the target and V120 for the urethra), which are
the only values provided by [47]. A robust algorithm is one that can deliver a high
dose to the target and low dose to the other organs such as the urethra, bladder,
or rectum. An overall better (more robust) algorithm can only be determined by
performing dosimetry planning using DOPAL on a number of test subjects, as well as
comparing DVH values from both algorithms that cover a greater variety of aspects.
This is planned for future work.
Another concern is related to the induced edema upon needle tissue interaction.
Edema is the abnormal accumulation of fluid beneath the skin, which may occur when
brachytherapy needles penetrate the skin to deposit seeds. This edema might even
cause the tumor size to change during seed implantation, thus reducing the degree
of accuracy of the dosimetry plan. If IDDO does not account for edema either, its
accuracy would be reduced as well. So the correct modeling of induced edema can
further improve the overall accuracy in brachytherapy.
Also, both DOPAL and IDDO currently work with only one type of seed - 125I, or
103Pd, but not both. It might be beneficial to expand the algorithms to use multiple
sources in the future, which could involve the expansion of the dose calculation module
to take into consideration the irradiation and interaction of two or more types of seeds.
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From an optimization point-of-view, even though good results were obtained for
dosimetry planning and seed compensation, the solutions to DOPAL and IDDO are
not globally-optimal. For example, the location of the initial seed tempseed affects
the outcome of the final seed configuration. In Fig. 4.10 for the 2D results, the
COM value was used as the initial tempseed location. However, if a very different
location was used as the initial temp.seed value, e.g., one on the boundary of the
contour slice, then the final seed configuration would be different to those shown in
Fig. 4.10. Therefore, although DOPAL’s DVH values and IDDO’s radiation coverage
all showed good results with sub-optimal results, this is a potential drawback for these
algorithms.
MIP might provide a global solution to these optimization problems, however the
discretized solution space might also reduce the accuracy that DOPAL and IDDO
currently possess. On the other hand, as was mentioned in [18], the solution to the
dosimetry planning problem might never satisfy all constraints. In other words, the
global solution may not exist for such a problem. And even if a global solution can
be found, it might take too long to arrive at that solution. It is worth noting here
again that one focus of the DOPAL algorithm is to address the problems that resulted
from time delay between pre-operative image-based planning and the implantation
stage. So as long as the currently sub-optimal solutions from the algorithms can be
proven to be clinically acceptable, it is still more advantageous over a time-consuming
globally optimal solution. Nevertheless, future work is planned in upgrading the
current algorithm implementation if a method can be found that provides an optimal
trade-off between the size of the solution space and the speed to arrive at a solution.
Finally, precise contouring of the implanted tumors using US images was some
times difficult, as was the case with ex vivo lung tumors, where the vessels and air
ducts made contouring of the tumor difficult even if the lung had already been col-
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lapsed. However, the US images have only been used to compare pre-planning results
from DOPAL with the results from RDP, so there are options of employing other high
quality imaging modalities in the future for contouring, such as x-ray. Furthermore,
experimental in vivo testing on animal models is planned for the near future.

5.3

C oncluding R em arks

In summary, this thesis presented the development of a dosimetry pre-planning algo
rithm (DOPAL) and an intra-operative dynamic dose optimization algorithm (IDDO),
which can be used in a robot-assisted brachytherapy procedure for the prostate, lung
and other organs. In the proposed algorithms, there are no pre-defined shapes for
which they can work with. Thus although the focus of this thesis has been on the lung
and the prostate, the algorithms have actually been designed to work with a range of
cancer tumors. Even though commercial software can also be used in a robot-assisted
brachytherapy procedure, the results in section 4.2.3 and 4.2.4 clearly show that they
cannot provide the accuracy comparable with those from DOPAL and IDDO.
The main achievement of DOPAL is on-line real-time dosimetry planning. In doing
so, two potential sources of error linked with the current brachytherapy method are
addressed. The first error is related to the reduced accuracy of the dosimetry plan
from the time of its creation to the time of its use. In the current brachytherapy
procedure, especially with regard to the prostate, there is a long waiting time (usually
several weeks) between the pre-plan and the seed implantation. The tumor’s size is
likely to have been enlarged by the time seed implantation takes place, making the
pre-plan not as accurate anymore. DOPAL is able to perform dosimetry planning
right before seed implantation, so the pre-plan produced by DOPAL is based on the
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shape of the tumor at seed implantation, thereby making the pre-plan as accurate as
it can possibly be.
The second issue is also related to the accuracy of the pre-plan, this time due
to errors in the images used for pre-planning and seed implantation. In the current
procedure, dosimetry planning is performed based on images acquired during pre
operative imaging with the patient in lithotomy position. When seed implantation
takes place (based on the dosimetry plan created), the patient is again placed in
lithotomy position but most likely not in the exact same way. Due to this difference
in how the patient has been placed between the pre-operative imaging stage and the
seed implantation stage, the images for the dosimetry plan are going to be different
from those for seed implantation. Thus, the intended locations from the dosimetry
plan could be inaccurate. DOPAL is able to perform dosimetry planning in real-time,
meaning that the exact same images that are used for dosimetry planning are also
used for seed implantation. Therefore, making the pre-plan more accurate than the
current method.
In addition, the upper and lower limits of the dose delivered to the target volume
can be adjusted as required. So in the event that a different dose needs to be admin
istered to a particular organ, the desired dose can be separately specified for each of
the organs present, such as the case for the prostate tumor, where the imposed f/&
and Ljj on the urethra and prostate were given different values from each other to
obtain a high dose to the prostate but a low dose to the urethra. In reference [47],
a similar approach is also described. In contrast, commercial software such as RDP
does not offer this flexibility, which might have lead to the poor dosimetry results in
Tables 4.4 and 4.5. In these tables, the urethral dose from RDP are as high as the
prostate dose, when in fact the dose to the urethra should have been much lower.
The main achievement of IDDO lies with the real-time compensation for seed
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misplacements. As mentioned earlier in this thesis, seed misplacements may occur
due to inaccurate seed deposition by the physician or robot. If the remaining seeds
are still deposited according to their original plan, the overall coverage of the tumor
is going to be different from the intended coverage as a result of these misplacements.
IDDO is able to compensate for any seed deviations from their intended locations by
generating new locations for the remaining seeds, such that the overall coverage at
the end of the procedure is as close to the intended coverage as possible.
Similar to RDP, both DOPAL and IDDO also provide the option to exchange the
type of seeds to be implanted, for instance between 125I or 103Pd, or even amongst
different types of 125I. Each type of seed has different radiation properties, and thus
the values involved in dose calculation are also different. These values for the chosen
seed type for this thesis, type 6711 of 125I, have all been stored in an individual file
which can be called-upon when performing dose calculation. These values are given
in Appendix B for reference. There are no limits on the number of seed types that
DOPAL and IDDO can work with, accurate results can be obtained as long as there
is a file that contains the values of the corresponding radiation parameters.
The algorithms can be used as stand-alone components or they can be used
together. Either use of the algorithms must be accompanied by a robot-assisted
brachytherapy set-up, one such set-up is the AESOP which was described in sec
tion 4.1.1.2. The aim of either use is to minimize the errors present in the current
brachytherapy procedures and to improve the overall radiation coverage results. The
algorithms have been tested experimentally using artificial tumors of different sizes
embedded in ex vivo porcine lung tissue and prostate phantoms. The outcome of the
tests have shown superior performance in comparison with a commercially available
software.
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P r o sta te Specific A n tigen

Prostate Specific Antigen (PSA), is a protein (glycoprotein of the kallikrein family kallikrein 3) produced by the cells of the Prostate Gland. The size of the prostate
gland is similar to that of a pea at birth, and it continues to grow as the man ages. By
the time the child has reached puberty the size of the prostate is doubled. The size
of the prostate of an adult is comparable to that of a walnut. The prostate specific
antigen is found in small quantities in the serum of normal men, whereas in men with
prostate cancer or other prostate disorders, the quantities of PSA are usually elevated.
Table A.l shows the normal PSA values for men of different races from different age
groups [64]. PSA is useful in the early detection, staging and follow-up of patients
who have prostate cancer [65]. A PSA level of 4ng/ml or under are considered normal
while level over 4ng/ml are considered abnormal.
Table A.l: PSA values for different ages groups and races
Caucasian Blacks Asian
Age
2
2
2.5
40~49
4
3
3.5
50~59
4
4.5
4.5
60~69
5
5.5
70~79
6.5
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The possible cause of prostate cancer is unknown, but it is thought to be mostly
related to unhealthy diet, age, genetics, heredity, etc. Measuring PSA level in blood,
known as a PSA test, is the most effective way right now to determine prostate can
cer. A rise in PSA levels over time indicate prostate cancer or benign (not cancerous)
conditions. The most common form of benign condition is Benign Prostatic Hyper
plasia, which is the englargement of the prostate gland; or Prostatitis, which is the
inflammation or infection of the prostate gland [66]. Therefore, a single level of PSA
is an unreliable measure of the extent of the disease in this context.
Scientists at Michigan Medical School discovered a possible cause for prostate
cancer, their findings show that in prostate cancer cases, specific genes merge due
to a recurring pattern of scrambled chromosomes. The outcome of this research is
aimed at developing more accurate diagnosis of the disease, as well as improving its
treatment [67].
Recently, the BBC has reported that men with longer index fingers than their ring
fingers are less likely to develop prostate cancer. However, the lead of this research,
Dr. Helen Rippon also states that men with shorter index fingers does not imply that
they will definitely develop prostate cancer [68].

A .2

G leason Score

The Gleason score, or the Gleason grading system is the sum of two numbers that
classifies the grade or the stage of the prostate cancer. The first number defines the
most common tumor pattern and is given a number of 1 to 5, where 1 implies that
the cancerous prostate closely resembles healthy prostate tissue, and 5 implies that
the prostate gland is no longer recognizable. The second number defines the second
most common tumor pattern, and is numbered in the same way as the first number.
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Table A.2: Non-small cell lung carcinoma staging
TNM staging
Categories
T1 NO MO
Stage 1 A
T2 NO MO
Stage IB
T1 N1 MO
Stage 2A
T2 N1 MO
Stage 2B
T3 NO MO
TI N2 MO
T2 N2 MO
Stage 3A
T3 N1 MO
T3 N2 MO
Any T N3 MO
Stage 3B
T4 Any N MO
Any T Any N Ml
Stage 4

Thus the lowest Gleason score is 2, and the highest Gleason score is 10, which is the
worst prognosis. It is important to point out that a Gleason score of 4 + 3 = 7 is
more severe than a Gleason score of 3 + 4 = 7.
A Gleason score of 2 —4 is categorized as Grade 1 (Gl), a Gleason score of 5 —6
is categorized as Grade 2 (G2) and a Gleason score of 7 —10 is categorized as Grade
3 (G3) [65],

A .3

Lung C ancer Staging

The two most common classifications of lung cancer are Non-Small Cell Lung Carci
noma (NSCLC), and Small Cell Lung Carcinoma (SCLC), with the latter being less
common. SCLC is strongly associated with smoking, while lung cancer patients who
have never smoked before are commonly diagnosed with NSCLC [69]. For NSCLC,
the severity of the tumor is described by threes letter, T, M and N.
T stands for tumor size and invasiveness, which ranges from T1 to T4. T1 tumors
are < 3cm; T2 tumors are either > 3cm or extend into the main bronchus; T3 tumors
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extend into the chest, but may be operable; T4 tumors invade the mediastinum (the
area and organs between the lungs) and cannot be surgically resected. N stands
for Nodal involvement, which ranges from NO to N3. NO impies that there is no
regional lymph node metastasis; N1 implies metastasis to ipsilateral peribronchial
and/or ipsilateral hilar lymph nodes; N2 implies metastasis to ipsilateral mediastinal,
and/or subcarinal lymph node(s); and N3 is metastasis to contralateral mediastinal,
contralateral hilar, ipsilateral or contralateral scalene, or spraclavicular lymph node(s)
[70]. M stands for métastasés, where MO indicates no distant metastasis present while
Ml means distant metastasis is present.
In [71], NSCLC are further categorized as in Table A.2. It can be seen in this
table that Stage 4 is the worst diagnosis since the tumor is spreading as indicated by
Ml, with a one year survival rate of 19% and five year survival rate of 1% [72].

A .4

C linical S tagin g for P r o sta te C ancer

In prostate cancer, clinical staging is an expression of both tumor volume and extent
of disease (EOD). Clinical staging for prostate cancer uses the same TNM convention
as for lung cancer; more specifically, T refers to the size of the primary tumor in
the prostate (T1 to T4); N refers to the involvement of and cancer spread to the
lymph nodes, where NO implies there is no regional lymph node metastasis and N1
implies there is metastasis in the regional lymph node(s); and M (métastasés) refers
to whether the cancer has spread to other body parts, where MO means there is no
distant metastasis and Ml means distant metastasis is present [73].
Furthermore, there are four categories that further classify the clinical stage of
the primary tumor (T) [65, 73], which is given below in Table A.3.
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Table A.3: Clinical staging of primary tumor (T)
Clinically inapparent tumor not palpable or
T1
visible by imaging
Tumor incidental histological finding in 5% or less
T la
of tissue resected
Tumor incidental histological finding in more than
T ib
5% of tissue resected
Tumor identified by needle biopsy (e.g. because of
T ic
elevated PSA)
T2
T2a
T2b

Tumor confined within the prostate
Tumor involves one of the prostate gland’s two lobes
Tumor involves both of the prostate gland’s two lobes

T3
T3a
T3b
T3c

Tumor extends through the prostate capsule
Unilateral extracapsular extension
Bilateral extracapsular extension
Tumor invades the seminal vesicle(s)

T4
T4a
T4b

Tumor invades any of bladder neck, external
sphincter, or rectum
Tumor invades any of bladder neck, external sphincter
or rectum
Tumor invades levator muscles and/or the pelvic wall

Based on the T, N and M values given above, as well as the Gleason score grades,
there are also four groups that differentiate the severity of prostate cancer, which is
shown in Table A.4.
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Table A.4: TNMG stage grouping for prostate cancer
TNM staging
Categories
T la NO MO Gl
Stage 1
T la NO MO G2/G3
T lb NO MO Any G
T ic NO MO Any G
Stage 2
T l NO MO Any G
T2 NO MO Any G
T3 NO MO Any G
Stage 3
T4 NO MO Any G
Any T NI MO Any G
Stage 4
Any T Any N Ml Any G
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D o se R ate

The Dose Rate (D (r)) for a point source approximation as given in [5] is as follows:

D(r) = Sk • A • g(r) ■G(r, 0) ■$an(r)

(B.l)

• Sh is the initial activity of the source in units of U, where 1U is equal to 1
unit of air kerma strength. The quantity hernia, which is short for kinetic
energy released per unit mass, refers to the amount of kinetic energy liberated
by uncharged particles such as photons from charged particles such as electrons
and positrons. The kerma can be expressed as joules per kilogram (J/kg ), which
is equivalent to the unit of absorbed dose, gray (Gy). Air kerma strength is a
measure of the brachytherapy source strength, which is defined as the product
of air kerma rate at a calibration distance, d, in free space, K(d), and the square
of the distance, d. K (d) is measured along the transverse bisector of the source.
So,

sk = k(d) ■d2

(B.2)
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Table B.l: Recommended dose rate constant in a water medium
cGy hr 1U 1
Seed
lyzfr
1.12
125I Model 6702
125I Model 6711
103Pd

0.93
0.88

0.74

So if kerma, time and distance are specified in units of //Gy, h, and m, respec
tively, then Sk will have units of //Gy m 2h _1 [5]. Then,
1

U = 1 ¡iGy m2 h 1

(B.3)

= 1 cGy cm'? h~l
The calibration of the source must be done at a distance d large enough so that
the source can be treated as a mathematical point. Though, it is customary
to specify the air kerma strength at a reference calibration distance, do, of lm.
Kerma rate, K , can usually be defined for a specific material at a point inside
a medium; in this case the medium is air. The unit of kerma rate is Jkg_ 1s_1,
and is given as the derivative determined from the amount of change in kerma,
dK, over the time interval, dt, i.e.,

dt

• A is the dose rate constant, the precise definition is given in [5] which basically
translates to the dose rate at a distance of 1 cm in water for a source with air
kerma strength of 1U. The 1cm used in determining the value of the source
is specified along the transverse axis of the actual source, as opposed to an
idealized point source. The dose rate constant is an absolute quantity, which
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accounts for geometric effects, source encapsulation, scattering in water, as well
as radioactivity and self-filtration within the source. The recommended dose
rate constant in a water medium is given by [5] in Table B.l.
Three models of the 1251 seed are mentioned in [5], they are the 6711 model, 6702
model and the 2300 model. However, only the first two models are described
in detail in [5]. Since sufficient information has been provided by [5] for the
6711 model of the 125I seed, it is chosen for this thesis. Due to the fact that
the human body can be considered as a water medium for research purposes, a
value of 0.88cGf//i_ 1[/- 1 is used for A in Eq. (B.l) [5].
• g(r) is the radial dose function, which accounts for absorption and scattering
effects in the medium along the transverse axis of the source. The values for
g(r) at different distances along the transverse axis areis given in Table B.2. As
is evident from the data in Table B.2, the values of g(r) define the falloff of dose
rate along the transverse axis due to absorption and scattering in the medium.
• Due to the spatial distribution of activity within the source, the relative dose is
varied. This variation is accounted for by the geometry factor G(r,0), which
can be approximated as

for a point source [5]. It ignores the effects due to

photon absorption and scattering in the source structure.
• ^an{f) is the anisotropy factor. Though as suggested in [5], for the 6711 model of
the 1251 seed, <
Pan(r ) can be approximated by a distance-independent constant,
<Pan, which is called the anisotropy constant and is usually less than 1.00. The
particular value used in this thesis for the 6711 model of the 125I seed, which is
given in [5], is 0.93.
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Table B.2: Radial dose function, g(r)
Radial dose function, g(r)
Distance along
transverse axis(cm) 125I Model 6711 125I Model 6702
1.04
1.04
0.5
1.00
1.0
1.00
0.934
0.926
1.5
0.832
0.851
2.0
0.760
0.731
2.5
0.632
0.670
3.0
0.541
0.586
3.5
0.511
4.0
0.463
0.445
0.397
4.5
0.344
0.389
5.0
0.341
5.5
0.300
0.264
0.301
6.0
0.233
6.5
0.266.,
0.204
0.235
7.0

B .2

D ose

In order to calculate the dose at a particular point, a conversion is required to convert
D{r) to D(r).
The mean life of a radionuclide is given by

(B-5)

where A is the decay constant of the source radionuclide, and
ln(2)
T \/2

and T i / 2 is the half-life of the radionuclide.

(B.6)
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Equation (8.56) in [7] is equivalent to Eq. (B.7) for a point source approximation,

D(r) = £)(r)r(l —e” )

(B.7)

_T

where e r « 0 for LDR in particular, since for permanent implants (LDR), T, the
irradiation time, is much higher than the mean life of the radionuclide r, so T > r.
For a source whose r is expressed in hours, the corresponding value of the time
conversion factor ku (expressed in hours) is equal to 1. Therefore, the dose for a 1251
source with a half-life of 1426 hours, is given by
D (r) = D (r) ■t ■ku
T
= S k - A g ( r ) - G ( r , e ) - * a n ^ (B.8 )
= Sk ■0.88 •

g(r)■- t • 0.93 • 1.443 • 1426 • 1
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R ad iation

The most significant effect of ionizing radiation is the damage to cells, mainly through
damage to the Deoxyribonucleic Acid (DNA). Even subtle damage to the DNA could
lead to mutations, which would further lead to cancer. When the dose is high enough,
radiation effectly kills cells [74], Generally speaking, cells under rapid division are
more sensitive to damage by radiation, such as the gonads in males and the uterine
area in females, as compared to muscles and nerves that divide slower and are not
easily damaged. In a way, this could be understood as that the radiosensitivity of a
cell type is proportional to its rate of division [75].
The two broad categories of radiation-related effects in humans are stochastic
and nonstochastic [75]. Effects that are generally observable soon after exposure to
radiation are called nonstochastic effects. Some examples of the damage done by
ionizing radiation for this category include depression of bone marrow cell division,
or NVD (nausea, vomiting, diarrhea) that is often observed in victims after radiation
exposure in the central nervous system. Here, a few examples are given regarding the
effects due to various amount of doses [74],
• 2 to 3 Gy to the skin can result in the reddening of the skin, similar to a mild
sunburn. May also result in hair loss due to damage to hair follicles.
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Table C.l: Differences between stochastic and nonstochastic radiation effects
Characteristic effects of
Characteristic effects of
Stochastic Effects
Nonstochastic Effects
A threshold exists below which
A threshold may not exist
the effects will not be observed
The magnitude of the effect increases The probability of the effect
increases with dose
with dose above this threshold
Effect cannot be definitively associated
Effect is clearly associated with
with the radiatione exposure
the radiation exposure

• QGy to the ovaries or testicles can result in permanent sterilization.
• 0.5Gy to the thyroid gland can result in benign tumors, which are noncancerous.
The Gray (Gy) is the SI unit for the absorbed dose, which is defined by [76] as a
measure of energy deposition in any medium by any type of ionizing radiation. 1 Gy
is equivalent to 1 joule of energy per kilogram of mass. The mathematical equation
for absorbed dose is [7],
_ de _ 1 de
dm
pdV
where de is the mean energy imparted in a volume of mass dm, and dm = pdV.
The traditional unit for absorbed dose is rad, where 1 rad is the equivalent of 1cGy
(centigray) and lOOcGy is equal to 1Gy.
The other category of radiation-related effects, stochastic effects, are effects that
are probabilistic. Examples of this type of effects include cancer induction and ge
netics effects that may affect offspring. The three important characteristics that
distinguish between the two categories are given in Table C.l.
Together with the abosorbed dose described above, there are three other quantities
that are of interest to radiation measurements, and they are the equivalent dose,
radioactivity and exposure [74]. The equivalent dose takes into consideration that
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not all types of radiation would have the same effect in biological systems. Thus it
is necessary to apply a quality factor (Q) which essentially represents the ability of
the particular type of radiation to cause damage [76]. Mathematically, the equivalent
dose is expressed as,

equivalent dose = absorbed dose x Q

(C.2)

where the SI unit for equivalent dose is the Sievert (Sv), and the absorbed dose is
in units of Gy. The value of Q is 1 for x-rays, 7 -rays and electrons, while for alpha
particles, the value of Q is 20. The sievert is a very large dose of radiation. A more
useful unit is the millisievert (mSv). The dose received by human beings around the
globe due to cosmic background radiation is about 3m Sv per year. The traditional
unit for equivalent dose is rem, short for Röntgen Equivalent in Man. 1 rem is equal
to O.OlSu.
A precise definition for exposure is given in [75], which basically translates to the
sum of one type of ion produced by radiation, divided by the mass of air. The SI unit
of exposure is C/kg, whereas the traditional unit is the Röntgen (R), which is the
same as 2.58 x 10—4C'/A:^.
The radioactivity is defined as the number of nuclear transformations per unit
time occurring in a given sample of radioactive material. Mathematically, this can be
defined as,
„

dN
dt

where dN is the number of decays observed during the time interval dt. The tradi
tional unit of radioactivity is the Curie (Ci), which is equal to 3.7 x 1010 transfor
mations per second. The SI unit for radioactivity is the Becquerel (Bq), which is
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Table C.2: Units used in measuring ionizing radiation
Units
Definition
SI unit: gray (Gy)
1 Gy = lJ/kg
The amount of energy
Historie
unit: rad
Absorbed dose
deposited per unit mass
1 rad = 100 erg/g
100 rad = 1 Gy
SI unit: sievert(Sv)
SI unit: Sievert (Sv)
Product of the absorbed dose
Historie unit: rem
Equivalent dose
and the quality factor Q
rem=rad x Q
1 Sv = 100 rem
SI unit: Becquerels (Bq)
Historie unit: Curie (Ci)
The number of decays over
Radioactivity
1 Bq = 27 pCi
a given time
1 Ci = 37 billion Bq
The Röntgen is defined as the
SI unit: C/kg
generation of 1 electrostatic
Exposure
Historie unit: Röntgen (R)
unit of charge per 1 cm3
of air
Quantity

equivalent to a single transformation, so that 1Ci = 3.7 x 10w Bq. Table C.2 presents
the quantities mentioned above, along with their SI and traditional units.
In the United States, brachytherapy sources are still sometimes specified according
to the traditional units. For instance, the nominal value of a 125I source may be
specified as OAlmCi (range 0.16 to 1 mCi) [9], instead of using the SI units.
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R a d io a ctiv ity o f 125I

Iodine 125, or 125I, is currently the most commonly selected source for low dose rate
brachytherapy, especially for permanent interstitial implants for prostate cancer [7].
It is an isotope of ^27I. The 125I radionuclide was discovered in 1946 by Allen Reid
and Albert Keston, though the clinical use of 125I for interstitial brachytherapy did
not take place for another 20 years [7]. 125I is usually created from 125Xe, which is
usually created from 124Xe in a nuclear reactor. The decay chain of 125I is shown
below in Eq. (D.l),
5? *

e - J jI 5 I

Te

(D.l)

T ij 2 associated with 525Xe is 16.9h while T^ 2 associated with ^25I is 59.49d.
1251

decays to the first excited state of 125Te through electron capture, a process

during which 1 electron had been sacrificed. 7% of the de-excitation to the ground
state of 125Te is via emission of a 35.5keV 7 -ray, which is also known as gamma
decay. Meanwhile, 93% of the de-excitation is through internal conversion, which
gives rise to characteristic x-rays. Model 6711 employed by this research emits silver
characteristic x-rays with energies of 22.1 and 25.5keV. The average photon energy
for this type of seed is 27AkeV, with an average of 1.4 photons being emitted for
every disintegration of 125I.
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Since the energy of the emitted photons is very low, minimum effort is required
regarding shielding thus making the handling of the sources easy and safe. In partic
ular, the HVL, or Half Value Layer, of lead for 125I is as thin as 0.025mm [6]. HVL is
defined as the thickness of the material, usually lead, required to reduce the radiation
of a source to half of its original amount. Therefore, a radioactive source that emits
high energy photons usually requires a higher HVL value.
Although the main current application field of 125I radionuclide is for low dose
rate prostate brachytherapy, it has also been used for permanent interstitial implants
for lung, pancreas and breast cancer; as well as temporary and permanent interstitial
implants for brain tumors [7].

